CA2191352C - Quinoline derivatives as tachykinin nk3 receptor antagonists - Google Patents

Quinoline derivatives as tachykinin nk3 receptor antagonists

Info

Publication number
CA2191352C
CA2191352C CA002191352A CA2191352A CA2191352C CA 2191352 C CA2191352 C CA 2191352C CA 002191352 A CA002191352 A CA 002191352A CA 2191352 A CA2191352 A CA 2191352A CA 2191352 C CA2191352 C CA 2191352C
Authority
CA
Canada
Prior art keywords
mmol
disorders
dissolved
compound
dryness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002191352A
Other languages
French (fr)
Other versions
CA2191352A1 (en
Inventor
Carlo Farina
Giuseppe Arnaldo Maria Giardina
Mario Grugni
Luca Francesco Raveglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline SpA
Original Assignee
SmithKline Beecham SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT94MI001099A external-priority patent/ITMI941099A1/en
Priority claimed from IT95MI000494 external-priority patent/IT1293558B1/en
Application filed by SmithKline Beecham SpA filed Critical SmithKline Beecham SpA
Priority to CA002257662A priority Critical patent/CA2257662C/en
Publication of CA2191352A1 publication Critical patent/CA2191352A1/en
Application granted granted Critical
Publication of CA2191352C publication Critical patent/CA2191352C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

NK3 receptor antagonists of formula (I) are useful in treating inter alia pulmonary disorders, CNS disorders and neurodegenerative disorders.

Description

wo ssl32s4s 2 I q t 3 5 2 The presenl invention relaoes to novel quinoline derivatives, processes for their preparation and their use in medicine.
- 5 The ".A",~,AT, . peptide Neurokinin B (NKB) belongs to the Tachykinin (TK) peptide family which also include Substance P (SP) and Neurokinin A (NKA).
P~ ei -~ and molecular biological evidence has shown The exisoence of three subtypes of TK receptor (NKI, NK2 and NK3) and NKB binds rrPfPrPn~iAlly to the NK3 receptor although it also recognises the other two receptors with lower affinity (Maggi et al, 1993, ~. Auton. Pl.,~l ' 13, 23-93).
Selective peptidic NK3 receptor antagonists are known (Drapeau, 1990 Regul.
Pep~., 31, 125-135), and findings wiLh peptidic NK3 receptor agonists suggest that NKB. by activating the NK3 receptor, has a key role in the modulation of neural input in airways, skin, spinal cord and nigro-striatal pathways (Myers and Undem, 1993, J.Phisiol., 470, 665-679; Counture et al., 1993, Regul. Peptides, 46, 426-429;
Mccarson and Krause, 1994, J. Neurosci., 14 (2), 712-720; Arenas et al. 1991, J.Neurosci., I l, 2332-8).
However, the peptide-like nature of the known antagonists makes them likely to be too labile from a metabolic point of view to serve as practical therapeutic agents.
We have now discovered a novel class of selective, non-peptide NK3 antagonlsts which are far more stable from a metabolic point of view than the known peptidic NK3 receptor antagonists and are of pooential therapeutic utility in treating pulmonary disorders (asthma, chronic obstructive pulmonary diseases -COPD-, 25 airway l.~ ,Lv;Ly, cough), skin disorders and itch (for example, atopic dermatitis and cutaneous wheal ~nd flare), neurogenic " and CNS disorders (Parkinson's disease, movement disorders, anxiety and psychosis). These disorders are referred to hereinafoer as the Primary Disorders.
The novel NK3 antagonists of the present invention are also of pooential therapeutic utiliity in treating convulsive disorders (for example epilepsy), renal disorders, urinary , ocular " '' y pain, eating disorders (food intake inhibition), allergic rhinitis, I..,.IIU~ ;V~; disorders (forexample ALzheimer'sdisease), psoriasis, Huntington's disease, and depression (hereinafter referred to as the Secondary Disorders).
According to the present invention there is provided a compound, or a solvaoe or salt thereof, of formula (I):

W0 95/32948 ` ` ~ I q 1 3 5 2 P~
F~2 ~
X~,,N--C--Ar _~R4 ' tI) in which 5 Ar is an optionally substituted phenyl, naphthyl or Cs 7 ~,lu~di."l~l group, or an opdonally substituted single or fused ring h~.t~u._~Lc group, having aronalic character, containing from 5 to 12 ling atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
R is linear or branched C1 8 alkyl, C3 7 cycloalkyl, C4 7 ."~ `' yl~ l, optionally 10 substituted phenyl or phenyl C1 6 aLlcyl. an optionally substituted five-membered L ' ring comprismg up to four heteroatom selected from O and N, hydroAy C1 6 alkyl, amino Cl 6 a~yl. C1-6 ~ ~ ~1, di Cl 6 al~, ' ' " ,~1, Cl 6 ~,~' ' '- yl, C1 6 alkoAyall~yl. Cl 6 -' yll,~ubull,~l, carboxy, C1 6 al~U~yA~allJUII,~I, Cl 6 a~u,~y~.ubul,~l C1-6 allcyl, ~1, C1 6 ~' y- - ' yl,diC1-6~- ~ Jl,halogenoC1 6all~yl;oris a group -(CH2)p- when cyclized onto Ar, where p is 2 or 3.
Rl and R2, which may be the same or different, are ;" ~ y hydrogen or C1-6 linear or branched aD~yl, or together form a -(CH2)n- group in which n represents 3, 4, or 5; or Rl together with R forms a group ~(CH2)q~~ in wbich q is 2, 3, 4 or R3 arld R4, which may be the same or different, are , ~ hydrogen, Cl-6 linear or branched al~yl, C1 6 aL~cenyl, aryl, Cl 6 allcoA-y, hydroxy, halogen, nitro, cyano, carbo-Ay" ~ ' ' ' . Cl 6 r' ~,~bu,.~l, i ^ ' yl, acylo-Ay, I ' - ' ' amino. mono- and di-Cl 6 aLIcylamino, -0tCH2)rNT2, in which r is 2, 3, or 4 and T is hydrogen or C1 6 aLlcyl or it forms with the adjacent nitrogen a group V, V
V (CH2~,, V ~
in which V and V l are; - -1~ r 1~ ~ ly hydrogen or oxygen and u is 0,1 or 2;
-O(CH2)s-OW2 in which s is 2, 3, or 4 and W is hydrogen or Cl 6 alkyl;
30 h~ ' UA~. '- yl, aminoalkyl, mono-or di-aLl~y' ' yl, acylamino, woss/32948 ' ~ ' ! , 2 ~ 91 352 all~ , mono- or di-aL~ , with up to four R3 ' being present in the quinoline nucleus;
or R4 is a group -(CH2)r when cyclized onto Rs as aryl, in which t is 1, 2, or 3;
Rs is branched or linear C 1-6 alkyl, C3 7 cycloalkyl, C1 7 cycloalkylalkyl, optionally substituted aryl, or an optionally substituted single or fused ring L,t~.u~"~.,L~
group, having aromatic character, containing from 5 to 12 ring atoms and comprising up to four hetero-atoms in the or each ring selected from S, O, N;
X is O, S. or N{~N.
Examples of Ar are phenyl, optionally substituted by hydroxy, halogen, Cl 6 aD~oxy or C1 6 aLlcyl. EAamples of halogen are chlorine and fluorine, an example of Cl 6 aLIcoAy is methoAy and an eAample of Cl 6 all~yl is methyl.
Examples of Ar as a ~,~lu,~,Lc group are thienyl and pyridyl.
EAamples of Ar as a Cs 7 .,~ . group is ."~1 ' ' ' ,1~, EAamples of R are as follows:
15 C1 8 ali~yl: methyl, ethyl, n-propyl, iso-propyl. n-butyl, heptyl;
phenyl Cl 6 all~yl: benzyl;
hydroxy Cl 6 al3cyl: - CH20H, -CH2CH20H, ~ (MP)(~;
amino C1 6 alkyl: -CH2NH2~
di C1 6 al~y' " yl. -CH2NMe2;
20 C1 6 allwA~l~yl. CH20Me;
Cl 6 aL~yl~ ,u~l~l. COMe;
Cl 6 all uA~ ubu.~l. COOMe;
C1 6 aLI~uA~ ubu,,~l C1 6 alkyl: CH2COOMe;
Cl 6 all~ 1. CONHMe;
25 di Cl-6 i~ 1. CONMe2, CO(I-pyrrolidinyl);
halogen Cl 6 all~yl: L zl, -(CH2)p- when cyclized onto Ar:
b~
Example of Rl and R2 as C1 6 alkyl is methyl;
30 eAample of Rl together with R forming a group-(CH2)q- is ~u~
Examples of R3 and R4 are methyl, ethyl, n-propyl, n-butyl, methoxy, hydroxy, amino, chlorine, fluorine, bromine, acetyloxy, 2-( ' ~I~Ili..o)ethoxy,
2-(1-phthaloyl)ethoxy, - ' y, 2-(l-u-~llul;dill~l)ethoxy~ phthaloyl, d,....,ll-,~ r U¦JUAj~ Jl~ o~ll~G~ O, a~,GiJ~ 1), 35 ~ 1 and phenyl.
Examples of Rs are cyclohexyl, phenyl optionally substituted as defined for Wo 95/32948 ~ 2 1 9 1 3 5 2 P~
Ar aboYe; examples of Rs as a l~. u., ~.,L,, group are furyl, thienyl, pyrryl, thiazolyl, benzofuryl and pyridyl A preferred group of compounds of formula (I~ are those in which:
Ar is phenyl, optionally substituted by C1 6 alkyl or halogen; thienyl or a Cs 7 cycloall~dienyl group;
R is C1 6 all~yl, C1 6 al~u~y~ul.~ l, Cl-6 aD~ ~lJu..~l, hydroxy C1-6 allcyl;
Rl and R2 are each hydrogen or Cl 6 alkyl;
R3 is hydrogen, hydroxy, halogen, C1 6 aLcoxy, Cl 6 alkyl;
R4 is hydrogen, Cl~ al~yl, Cl 6 alkoxy, hydroxy, amino, halogen, 1- y~mono-ordi-aLl~y' ' " y,mono-ordi ' ~ yl, ' ' ' yldl~ y,mono- ordi ~y' ' ~~ .~' ' andacylamino;
Rs is phenyl, thienyl, furyl, pyrryl and thiazolyl.
A further preferred group of ~- . ' of formula (I) are those in which:
Ar is phenyl, 2-.,l.lu.uu;..,...~l, 2-tbienyl or ~y l~
R is methyl, ethyl, n-propyl, -COOMe, -COMe;
R1 and R2 are each hydrogen or methyl;
R3 is hydrogen, methoxy, or hydroxy;
R4 is hydrogen, methyl, ethyl, methoxy, hydroxy, amino, chlorine, bromine, ~'' ' J' ' ' y, 2-tl-phthaloyl)ethoxy, ' ~ ' y, 2-(1-~" '' ' .~I)etho~y, ~" ~ r r acc~ ' and" ',~' ' ',~1.
Rs is phenyl, 2-thienyl, 2-furyl, 2-pyrryl, 2-thiazolyl and 3-thienyl;
and X is oxygen.
A preferred sub-group Of - -- -r - ' witbin the scope of formula (I) above is of formula (Ia):

o~,~ N--C--Z
~ R H (la) in which:
R, R2, R3 and R4 are as defined in formula (I), and Y and Z, which may be the same or different, are each Ar as deflned m formula (I) . . . _ . _ woss/32s4s ~ 2!91352 P~
A p~u Li~ y preferred group of ~ of formula (la) are those of formula (Ib) in which the group R is orienoed downward and H upward.
7.
R3~ C ~ (Ib) The . . ' of formula (I) or their salts or solvaoes are preferably in 1- - lly acceptable or ' ".~, pure form. By l,I .- . .":. .11~, acceptable form is meant. inoer aia. of a ~Jh ~ r; -lly aeceptaWe level of purity e~cluding normal r' ' ' additives sueh as diluents and car~iers, and ineluding no maoerial considered toxie at normal dosage levels.
10 A ~ub~ ly pure form wil generally eont~un at least 50% (e~cluding normal ~1. , ._. ~ :;, ~1 additives), preferably 75%, more preferably 90% and still more preferably 95% of the compound of formula (I) or its salt or solvaoe.
One preferred ~ aeceptable form is tbe erysta7 ine form, including such form in I ' ~. ,..~ In the case of salts and solvaoes the 15 additional ionic and solvent moieties must also be non-toxic.
~ amples of I ' lly aceeptable salts of a eompound of formula (I) inelude the acid addition salts with the cu..~. ', ' ' acids, for example maleie, 7..~ ' h~u~.u~;." ~- . - aeetic, fumaric, saieylic, eitrie, ~ede, mande ie, ta~tarie, sueeinie, benzoie, ascorbie, and ' l ' 7~amples of l~h~ - t;- A71y aceeptable solvaoes of a compound of formula (I) include hydraoes.
The r ' of formu a (~) may have at least one asymmetric centre and therefore may e~ist in more than one form. The invendon e~oends to all such forms and to mixtures thereof, ineluding racemaoes.
The invendon a.7so provides a proeess for the preparation of a eompound of formu a a) whieh eomprises reaeting a eompound of formula (m) H ~A~
R' (m) in whieh R', R'l, R'2 and Ar' are R, Rl, R2 and Ar as defined for formula (I) or a group or atom eonvertible to R. Rl, R2 and Ar, with a eompound of formula (II) wossl32s4s ~ i ` 2 1 9 1 35~
X' OH
R 3~R~4 (II) or an active derivative thereof, in which R'3, R'4, R's and X' are R3. R4, Rs 5 and X as defined for formula (r) or a group convertible to R3, R4, Rs and X, to form a compound of formula (Ic) R, 2 R~
R.~3~R~,R,l (Ic) and optionaDy thereafter performing one or more of the following steps:
(a) where R', R'l to R'5, Ar' and X' are other than R, Rl to Rs, Ar and X, conver~ing any one of R: R'l to R'5, Ar' and X' to R, Rl to Rs, Ar and X to obtain a compound of formula (I), (b) where R', R'l to R'5, Ar' and X' are R, Rl to Rs, Ar and X, converting any 15 one of R, Rl to R5, Ar and X to another R, Rl to Rs, Ar and X, to obtain a compound of formula a), (c) forming a salt and/or solvate of the obtained compound of formula (Ic).
Suitable active derivatives of the compounds of formula (II) are acid halides (preferably chlorides), acid azides or acid anhydrides. Another suitable derivative is a 20 mixed anhydride formed between the acid and an aDyl Cl.1UI~ ~ , another suitable derivative is an activated ester such as a ~"~ ' yl ester, tbiophenyl ester, p r' ~. ester, p ' , ' jl ester, 2,4,6-L~i~hlull, ' Jl esoer, ' ' , ' ~1 ester, ~ 1 ester, N-hydroxy-phtalimido ester, N-I~Lw~y~ id;l.~ ester, N-l~y~Lu~ ' ester, N-hydroxy Ir - 1 ;,.,(,1F ester;
25 or the carboxy group may be activated using a ~' - " ' or N,N'-For example, in standard methods weD known to thoæ sl~lled in the art, the' of formula (m) may be coupled:
(a) with an acid chloride in the presence of an inorganic or organic base in a 30 suitable aprotic solvent such as ~ (DMF) as a ~ r in a W095132948 : ! 2 ~ 91 352 r~
range from -70 to 'i0C (preferably in a range from -10 ~o 20C), (b) vith the acid in the presence of a suitable condensing agent, such as for e~ample N,N'-carbonyl ~ 17tllf' (CDI) or a ~ - ~o~l;; ; 1~ such as ~ ,lùl._~yl~l)f ' ' (DCC) or N-d....~,d-~ , u~uyl-N'~Lh.~ J~J~
5 and N-~ l,u"~ (HOBT) to maximise yields and avoid ~
processes (Synthesis, 453, 19 72) in an aprotic solvent such as a mixture of acetonitrile (MeCN) and ~.~ lur~ ul CI~ ) in a ratio from 1: 9 to 7: 3, .~Li~ , at a in a range from -70 to 50C (preferably in a range from -10 to 25C) (see Scheme 1), woss/32s48 f ' ` 2 1 9 1 3 52 Scheme 1 Oq~OH R N;2 COOMe R~ N~OOMe R3~;R' tll) (111) (Ic) ~c) with a mixed anhydride generated in situ from the acid and an all~yl ~for example isopropyl) ~ in a suitable aprotic solvent such as d;~hl~ t~ at a i . in a range from -70 to 50C ~preferably in a range from -20 to 20C).
It will be arr ~ that a compound of formula (Ic) may be converted to a compound of formula (I), or one compound of formula a) may be converted to another compound of formula a), by ~ ll of suitable ' Thus, certain c--lr ' of formula (I) and (Ic) are useful in forming other ~ of the present invention.
For example R'2 may be hydrogen and converted to R2 alkyl group, for e~ample 15 methyl, by c~ uu~l amide alkylation procedures (Zabicky, The ch~n~stry of amides; T..t~ London, 1970, p. 749). When X' is o-Aygen, it may be converted to X sulphur by standard thioamide formation reagents, such as P2S5 (CheL Rev.,61, 45, 1961 orAngew. ChenL, 78, 517, 1966) or the Lawesson reagent (Tetrahedron, 41, 5061, 1985). When Ar' or R'5 is a metho-Ay substituted phenyl, it may be 20 converted to another Ar' or R'5 hydro-Ay substituted phenyl by standard d~ hyl~L;~
procedures via Lewis acids, such as boron tribromide (Synthesis~ 249, 1983) or mineral acids, such as l.yl' ' or hydroiodic acid. When R is an ~uAy~ubu..~l group, for example l~ lluAy~bull~;, it may be converted to another R such as i ' y~u..JI by i with atl appropriate alcohol at a /~ --.. in a range from 20 to 120C, carboxy by hydrolysis in acidic or basic medium, b~ ~I,al~y' bu~;or~ ' ' ,Ibyi ' with ammonia, a primary amine or a secondary amine in methanol as solvent at a in a range from 10 to 120C, optionally in the presence of a catalytic amount of NaCN (J. Or~. Chem., 52, 2033, lg87) or by using IliA~ Y' ' (Me3Al) (Tetrahedron Letters, 48, 4171, 1977), ll~UA~ h~,l by a selective metal hydride reduction, such as lithium bulully-Li~ reductiorl (Tetrahedron, 35, 567,1979) or sodium bulully~ reduction in THF + MeOH (BuL Che~L Soc Japan, 57, 1948, 1984 or Synth. Coraml~n., 12, 463, 1982), ' yl~ u..11 by acyl chlorideformation and subsequent reaction with ~' " halides in THF as solvent at ... ........... .. . . .. .. .. . . . . . . . . ... .... . .. . .. . . .

wo 9~/32948 '~ 2 1 9 1 3 5 2 PCr/EPss/02000 a r ~ in a range from -7O to 30C (Te~rahedron Le~ers, 4303.1979) or with '- ~luaLI~ u halides or diaLl~yl~a~,...,.l. in the presence of MgC12 or LiCI (~. Org.
CfzerrL, 47, 2590, 1982). Another group which R' as ~ hvA.y~albull~; can be converoed into is a substituoed ll~lualv..laLi~ ring, such as an oAadiazole (J. Med 5Chem., 34, 2726,1991).
Scheme 2 some of the above described procedures to convert a compound of formula ac) or (I) in which X' is oAygen, R' is COOMe, Ar' and R'l to R'5 are as described for formula (I) to another compound of formula (1).
10 Scheme 2 R'3~R' ~NHM~
o N~OOMe / \ 1) NH o N~H20H
HO~ o N~A~' ~ RR R~
R3~ RRR', 1)(COCO
2) Al~t. THF, -78 C
N 2 COMe R.~`R', The compounds of formula (I) may be converted into their ~ lly acceptable acid addi.~ion salts by reacLon with the appropriate organic or mineral 15 acids.
Solvates of the ~ r ~ of formula (I) may be formed by cry~lli7~ti- n or recrystallizatiûn from the appropriate solvenL For eAample, hydraLes may be formed W0 95132948 `'' `.` ~ ``, i `` 2 1 9 1 3 5 2 F~
by crystqlli7~tion or -c~ from aqueous soludons. or solutions in oLganic solvents containing wateL
Also salts or solvates of the compounds of formula (I) which are not 1~ lly acceptable may be useful as ' in the production of ~
5 acceptable salts or solvates. Accordingly such salts or solvates also form palt of this invention.
As mentioned before. the . ' of formula (I) may exist in more than one form and the process of the invention may produce L~cemates as well as ~ pure forms. To obtain pure: appropriate 10 ~ - ;...,... ;. -lly pure priinary or secondary amines of formula (md) or (me) R 2 R~ H ~Ar' R', R', (~d) alle) 15 are reacted with :~ , ' of formula (II), to obt~un r ~ of formula (I'd) or (I'e).
~, X' N~A~
R 3~[~, R 1 R 3~R~s (I'd) (I'e) Cl . ' of formula (I'd) or (I'e) may ' . '~1 be converted to ' of formula ad) or (le) by the methods of conversion mentioned before.
,R2 R ~ ~Ar Ra~lRrrl R3~rs ad) (Ie) Cl . ' of formula (Il) are known compounds or can be prepared from known .... ~ , ' by known methods.
For example, the compound of formula (II), in which X' is oxygen, R'3, R'4 21~1352 wo ss/32s4s ` ' ' r~
and R~5 are hydrogen is described in Mltzinger, J. Prakt. Chem., 38, 582,1882 and in Pfitzinger, J. Prakt. Chem., 56, 293,1897; the compound of formula (~), in wmch X' is oxygen, R'3 and R'4 are hydrogen and R's is 2-pyridyl is described in Risaliti, Ric.
Scient., 28, 561,1958; the compound of formula (~), in which X' is o-Aygen, R'3 and 5 R'4 are hydrogen and R'5 is o-, m- andp-chlorophenyl. o-lluu."~ ~1 and 3,4-1 are described in Brown et aL, J. Am Chem. Soc., 68, 2705,1946; thecompound of formula (II), in which X' is o~ygen, R'3 and R'4 are hydrogen and R's is p ' ~ 1 is described in Ciusa and Luzzatto, Ga~ Chim. ItaL, 44, 64,1914;
the compound of formula (Il), in which X' is oAygen, R'3 and R'4 are hydrogen and 10 ~5 is ~n-i r~ uu~ is described in Shargier and Lalezari, J. ChenL Eng.
Dara, 8, 276,1963; the compound of formula (lI), im which X' is o~ygen, R'3 and R'4 are hydrogen and R'5 isp-r' r ~ ~1 is described in Bu Hoi et aL, Rec Trav. Ch~m., 68, 781, 1949; the compound of formula (~), in which X' is o-Aygen, R'3 and R'4 are hydrogen and R'5 isp-.u"~lJ~ ; is described in Prevost et al., Cornpt. Rend Acad Sci., 258, 954,1964; the compound of formula (I[), in which X' is oAygen, R'3 and R'4 are hydrogen and R'5 is p-bl . ' yl is described in Nicolai et aL, Eur. J.
Med Chem, 27, g77, 1992; the compound of formula (1[) in which X' is oAygen, R'4and R's are hydrogen and R'3 is 6-methyl is described in Buchmann and Howton, J.Am. Chem. Soc., 68, 2718,1946; the compound of formula (~), in which X' is oxygen, R~4 and R~5 are hydrogen and R'3 is g-nitro is described in Buchmann et al, J.
Ar~ Chem. Soc., 69, 380,1947; the compound of formula (r[), in which X' is o~ygen, R'4 is hydrogen, R'3 is 6-chloro, R'5 is p~ 1 is described in Lutz et al., J.
Am. ChenL Soc., 68, 1813,1946; the compound of formula (Il), in which X' is oAygen, R'3 and R'4 are hydrogen and R'5 is 2-thiazolyl is described in Eur. Pat.
Appl. EP 112,776; compounds of formula (~), in which X' is oAygen, R'3 is 8-' yl, R'4 is hydrogen and R's are phenyl, o- and p-Lluulu~ l, 3,4-~ lllul~ P ~ 1 are described in Nicol~d et aL, Eur. J. Med Cher~L, 27, 977,1992; - r ~ of formula (Il), in which X' is o~ygen, R'3 is 6-bromo, R'4 is hydrogen and R'5 are phenyl orp-lluv ul~h~ are described in Nicolad et aL, Eur.
J. Med. Chem., 27, 977, 1992; other '~U--r ' of formula (~) are described in Geir.
Offen. DE 3,721,222 and in Eur. Pat. Appl. EP 3~'4,313.
~' . ' of formula (m), (md) and (me) are, 'Iy available ' or can be prepared from known r by lcnown methods (for e-Aample, ~ . ' of formula (m) in which R' is a'~uAy~ul,v..zl, R'l and R'2 are 35 hydrogen and Ar' is as defuned for the . . ' of formula (1), are described in LiebigsAnn. der Chemie, 523, 199,1936).
The activity of the compounds of formula (I) as NK3 receptor antagonists in standard tests indicates that they are of potential therapeutic utility in the treatment of W095132948 .,, ; 2 ~ 9 ~ 352 ~ P~ tr both the Priunary and Secondary Disorders herein before referred to.
The discovery that NK3 receptor ~nt~t.nictc have potential therapeutic utility in treating the Secondary Disorders is new, and in a further aspect of the present invention there is provided the use of an NK3 receptor antagonist for the treatment of 5 the Secondary Disorders. There is also provided the use of an NK3 receptor antagonist in the ~ of a - ' for the treatment of any of the Secondary Disorders.
The present invention also provides a compound of formula (I), or a ~,l - ,.... ,;. _l~y acceptable salt or solvate thereof, for use as an active therapeutic substance.
IQ The present invention further provides a ~
comprising a compound of formula (l), or a ph ., -. ~-";. ,.lly acceptable salt or solvate thereof, and a I ~ "y acceptable carrier.
The present invention also provides the use of a compound of formula a), or a l h; "~, acceptable salt or solvate thereof, in the r ' of a 15 ' for the treatment of the Primary and Secondary Disorders.
Such a ~ and a c~ u~ of this invention, may be prepared by admixture of a compound of the invention with an appropriate carrier. It may contain a diluerlt, binder, filler, .' ~, t, flavouring agent, colouring agent, lubricant or ., in ~,u..~. l manner.
These c ~ lti~)llal excipients may be employed for example as in the preparation of ,~V~hv..., of ktlown agents for treating the condidons.
Preferably, a ~ ' ' c~ of the invention is in unit dosage form and in a form adapted for use in the me&cal or veterinarial fields. For example, such l ~ may be in a pack form , ' by written or printed 25 inctrllrtir,nc for use as an a8ent in the treatment of the conditiotls.
The suitable dosage range for the f ' of the inventdon depends on the compound to be employed and on the condition of the padent. It will also depend,inter aLia, upon the relation of potency to ~l .,... l 1, l ly and the frequency and route of r' ' . ' The compound or ~ " "l"J-: ': - of the invention may be formulated for - ' by any route, and is preferably in unit dosage form or in a form that a human padent may administer to himself in a single dosage. Au ~ l~" the is suitable for oral, rectal, topical, parenteral, ;llh~ vw or ;..1 1 - r~p~,l~u~s may be designed to give slow release of 35 the acdve ingredient.
C~ . may, for exarnple, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, ' ' powders, or liquid l r~ 1;- - C. for example soludons or - ~ or ~
The ~ . . for example those suitable for oral - ' may woss/32s48 ~ ' ~ ' 21 91 3 52 r~ o contain l,Ull~lL U~ excipients such as binding agents, for example syrup, acacia.
gelahn, sorbitol, tragacanth, or pol~ JJ,l ' ' , fillers, for e-Aample lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example ~ - c ~ stearate; ~' ~ for example starch, polyviny~ ulidu,,ci,sodiumstarchglycollateor Ini,lUl,lJ ' "' cellulose;or , acceptable sethng agents such as sodium lauryl sulphate.
Solid ~ - may be obtained by l,v.l.~ iu~l methods of blending, filling, ubletting or the li~e. Repeated blending operations may be used to distribute the acdve agent throughout those . , ~ employing large quanhties of fillers.
10 When tne ~ l is in the form of a tablet, powder, or lozenge, any carrier suitable for r ' ' ,, solid ~ may be used, examples being _ stearate, starch, glucose, Iactose, sucrose, rice nour and chalk Tablets may be coated according to methods well known in normal ~
practice, in particular with an enteric coating. The , may also be in the 15 form of an ingeshble capsule, for example of gelatin containing the compound, if desired with a carrier or other excipients.
C , for oral - ' as liquids may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product forwith water or other suitable vehicle before use. Such liquid 20 .~ ;. . - may contdin ~UII~ ' ' addidves such as suspending agents, for e-Aample sorbitol, syrup, methyl cellulose, gelatin, h.~JIUA~lllJ' " ' ~ubu~ ' " ' , aluminium stearate gel, h.~ edible fats;
, agents, for example lecithin, sorbitan ' ~ or acacia; a~ueous or non-aqueous vehicles, which include edible oils, for eAample almond oil, r .
25 coconut oil, oily esters, for eAample esters of glycerine, or p}opylene glycol, or ethyl alcohol, glycerine, water or normal saline; ~lw~. vd~i~w~ for eAample methyl or propyl p h,~JIuA~b~ u~ or sorbic æid; and if desired ~u..., ' flavouring or colouring agents.
The . . ' of this invention may also be ~ ' ' by a non-oral 30 route. In accordance with rouhne r ' l procedure, the . , ' ' may be ' ' 1, for example for rectal r ' as a , ~ ~. They may also be formulated for r ' " in an injectable form in an aqueous or non-aqueous soluhon, suspension or emulsion in a l ' lly acceptable liquid. e.g. sterile pyrogen-free water or a parenterally acceptable oil or a mixture of liquids. The liquid 35 may contain l ~ agents, anti-oxidants or other ~ " buffers or solutes to render the solution isotonic with the blood, thickening agents, suspending agents or other ~ a~ Ally acceptable additives. Such forms will be presented in unit dose form such as ampoules or disposable injection devices or in multi- dose forms such as a bottle from which the appropriate dose may be withdrawn or a solid wo gsl32948 ~ 2 1 q 1 3 5 2 P~.l/rr form or concentrate which can be used to prepare an injectable r. ." ,. . ,1 ;,,"
The compounds of this invention may also be p~ - r~i by inhalation, via the nasal or oral routes. Such r can be carried out with a spray comprising a compound of the inYention and a suitable carrier, optionaUy 5 suspended in, for example, a hJJIu~ u~ propeUant.
Preferred spray ~ comprise micronised compound particles in r~ml ' ' with a surfact~int. solvent or a dispersing agent to prevent the of suspended paTticles. Preferably, the compound particle size is from about 2 to 10 microns.
A furt~er mode of ~ of the - r ~ of the invention comprises transdermal delivery utilising a skin-patch r " A prefer~ed r..., I l;, .., comprises a compound of the invention dispersed in a pressure sensitive adhesive which adheres to the skin, thereby permitting the compound to diffuse from tbe adhesive through the skin for delivery to the patient. For a constant rate of ~ u-- - absoryion, pressure sensitive adhesives known in the art such as naturalrubber or silicone can be used.
As mentioned above, the effecdve dose of compound depends on the pa~ticular compound employed, the condition of the patient and on the frequency and route of r A unit dose will generally contain from 20 to 1000 mg and preferably will cont iin from 30 to 500 mg, in particular 50, 100, 150, 200, 250, 300, 350, 400, 450, or 500 mg. The ~ may be r ~ once or more times a day for example 2, 3 or 4 dmes daily, and the total daily dose for a 70 kg adult wiU
normaUy be in the r~inge 100 to 3000 mg. Al~.l~~ the unit dose will contain from 2 to 20 mg of acdve ingredient and be - ' ~ in muldples, if desired, to give the preceding daily dose.
No I r ~ ~ lg;. Al effects are e~pected witi , ' of the inventdon when ' in accordtince with the inventdon.
The present inventdon also provides a method for the treatment and~or yluyhrl~ of the PrimaTy and Secondary Conditdons tn mammals, p~uL~
humans, which comprises - ' g to the mammal in need of such treatment and/or yluyll~ an effectdve amount of a compound of formula (I) or a yl ~ y acceptable salt or solvate thereo The invendon furlher provides a method for the treatment and/or ~uy~.~l~ of the Secondary Condidons in mammals, pardcularly humaris, which comprises ' _ to the mammal in need of such treatment and/or y~uyhJl~i~ an effectdve amount of an NK3 receptor antagonist.
The activity of the c--lr ' of the present inventdon, as NK3 ligands, is determined by their ability to inhibit the binding of the ~ , 11, d NK3 iigands,[125r-[Me-Phe7]-NKB or [3Hl-Senkdde, to guinea-pig and human NK3 leceptors woss/32s4s ~r ~ 352 PCT/E:P95/02000 (Renzetti et al, 1991, N~uropepride, 18, 104-114; Buell et al, 1992, FFRS, 299(1), 90-95; Chung el al. 1994, Biocher~L Biophys. J~es. Commun., 198(3), 967-972).
The binding assays utilized allow the ~ of the c n~ of the individual compound required to reduce by 50% the [125Il-[~e-Phe7]-NKB and 5 [3H]-Senktide specific binding to NK3 receptor in equilib}ium conditions (IC50).
Binding assays provide for each compound tested a mean ICso value of 2-5 separate performed in duplicate or triplicate. 'rhe most potent compounds of tne present invention show ICso values in the range 1-1000 nM; in particular, in guinea-pig cortex by ~' ~r~- of [3Eil-Senktide, the compounds of the E7 amples 22, 47, 48, and 85 display Kis (nM) of 5.6, 8.8, 12.0 and 4.8 I~,D~ ,1Y
(n=3). The NK3 - activiy of the compounds of the present invention is f ~'~ ~ by their ability to inhibit senktide-induced contraction of the guinea-pig ileum (Maggi et al, 1990, Br. J. F' 1., 101, 996-1000) and rabbit isolated iriD
sphincter muscle (Hall et al., 1991, Eur. J. rhl" ' 199, 9-14) and human NK3 receptors-mediated Ca~ ~r r~ ! (Mochizuki et al, 1994, J. BioL Cherr~, 269, 9651-965~). Guinea-pig and rabbit in-virro functional assays provide for each compound tested a mean KB value of 3-8 separate r .I. .; . ~t~ where KB is the ~ of the individual compound required to produce a 2-fold rightward shift in the ~ ._DpU.~ curve of senktide. Human receptor fimctional assay allows the ~ of the of the individual compoumd required to reduce by 50% (IC50 values) the Ca++ ' " induced by the agonist NKB. ln tbis assay, the , ~ of the present invention behave as antagonists.
The therapeutic potential of the ( . ' of the present invention in treating the conditions can be assessed using rodent diseac~e models The following DPcrrir~innc illustrate the preparation of the whereas the Examples i~ustrate the preparation of the compounds of the present invention. The '~-r ' of the Examples are ' in the Tables 1 to 6 DESCR~rION 1 2-,' J`S ~ ' acid chloride WO9~/32948 , :! ~; ' t~ 2 1 9 1 3 5 2 r~
11.7 ml (136.3 mmol) of oxalyl chloride were dissolved in 150 m~ of CH2Ck. The solution was cooled at -10C and 20 g (80.2 mmol) of 'Iy available 2-'q ' 1 carboxylic acid were added yollh~ ~. The reaction mi~ture wasleft overnight at room Lll.~ a~ ; and then evaporated to dryness to yield 22 g of the dtle compound, used without further M.W. = 267.76 DESCRIPrlON 2 7-me~oxy 2, ,' ~ L ~' acid 5 g (28.2 mmol) of ~ ., 4 ml (33.8 mmol) of )j' and 5.2 g ~92.6 mmol) of potassium hydrwdde were dissolved in 22.9 ml of abs. EtOH and theslurry heated at 80C for 42 hours. After cooling of the reaction mi~hore, 50 ml of 15 water were added and the solution e~tracted with 50 ml of Et20. The ice-cooled aqueous phase was acidified to pH I with 37% HCI and the precipitate collected by filh ation and washed with waoer.
The solid obtained was dried in-vacw at 40C to yield 7.0 g of the title compound.
Cl7H13N03 M.P. = 226-228C
M.W. = 279.30 Elemental analysis: Calcd. C,73.11; H,4.69; N,5.01;
Found C,72.07; H,4.59; N,4.90.
LR (KBr): 3420; 1630 cm~l.

7.me~oxy 2, ,1~, ' q ~; .~' a~d chloride 2.8 ml (32.3 mmol) of o~alyl chloride were dissolved in 60 ml of CH2C12. The 30 solution was cooled at -10C and 6 g (19.0 mmol) of 7-methoxy-2-L J S
4-carboxylic acid were added portionwise. The reaction mi~hore was left overnight at room ~. ~1, ,.h .. r and then eYaporated to dryness to yield 7 g of the title cornpound, used without further pllrifir~-jr,n C17H12clNo2 M.W. = 297.74 7-hydroxy 2 ~ , ' - 1 L ~ ' acidh~

WO 95/32948 r t ,, 2 1 9 1 3 5 2 PCT/EP95/02000 1.5 g (5.4 mmol) of 7-methoxy-2-~ ih~oli..~-4-carboxylic acid were added p~ ;~ to 50 ml of 57% aqueous Hl. The reaction mixture was refluxed and stirred for 5 hours; then it was evaporated in-vaCuo to dryness to yield 5 2.1 g of the title compound.
Cl6HllNo3~ Hr M W. = 393.17 LR. (RBr): 3120;1650;1620 cm~l.
0 DESCRlPTlON 5 ienyl). ' '' q ~ ,~'' acid 5 g (34.0 mmol) of isatin, 4.4 ml (40.8 mmol) of 2-a~t~ . and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40 ml of abs. EtOH and the slurryheated at 80C for 16 hours. After cooling of the reaction mixture, 50 ml of water were added and the solution extracted with 50 ml of Et2O. The ice-cooled aqueousphase was acidified to pH 1 with 37~ HCI and the precipitate collected by filtration and washed with water.
The crude product obtained was dried in-vacuo at 40C and triturated with EtOAc to0 yield 4.8 g of the title compound.

M P. = 181-183C
M.W. = 255.29 LR (RBr): 1620 cm~l.5 300 MHz lH-NMR (DMSO-d6): ~ 8.60 (d. lH); 8.45 (s. lH); 8.10 (m, 2H); 7.78 (m, 2H); 7.68 (t, IH); 7.22 (m, IH).
DESCRI~ION 6 2-(~fiLryl`~ L ~'' acid 5 g (34.0 mmol) of isatin. 4 ml (40.8 mmol) of 2-acetylfman and 6.3 g (112.2 mmol) of potassium hydroxide were dissolved in 40.9 ml of abs. EtOH and the slurry heated at 803C for 12 hours. After cooling of the reaction mixture, 50 ml of water wereadded and the solution extracted with 50 ml of Et2O. The ice-cooled aqueous phase 35 was acidified to pH 1 with 379~ HCI and the precipitate collected by filtration and washed with water. The crude product obtained was dried in-vacuo at 40C to yield 8.5 g of the title compoumd.

_ . . . _ .

wo ss/32s4s ~ 9 1 3 5 2 r~
M.W. = 239.23 DESCRIPTIO~ 7 2-(2-furyl`, ' ' q ' ,~' acid chloride s 5.2 ml (60.4 mmol) of oxalyl chloride were dissolved in 70 ml of CH2C12. The solution was cooled at -10C and 8.5 g (35.5 r~mol) of 2-(2-furyl), !i-~
carboxylic acid were added pU16iUll~ . The reac'don mi~ture was left overnighl atroom r ~ (tl-r. and then evaporated to dryness to yield 9.2 g of the title compound, 10 used without further ~ =
C14H8ClN02 M W. = 257.78 DESCRlPrlON 8 2 (q r,l.d~l`. ' ~ carboxylicacid h"l~
5 g (34.0 mmol) of isatin, 4.5 ml (40.8 mmol) of 4-~L~ ' and 6.3 g (112.2 mmol) of potassium hydro~ide were dissolved in 40 ml of abs. EtOH and the slurryheated at 80C for 12 hou}s. After cooling of the reaction mi~ture, 50 ml of water were added and the solution e~uacted viith 50 ml of Et20. The ice-cooled aqueousphase was acidified to pH 1 with 37% HCI and the precipitate collected by fltration and washed with water.
The aqueous solution was evaporated in-vac~o to dryness, the residue ttitu~ated with EtOH and filtered off. ~r~ula~iûll of the solvent afforded 6.0 g of the crude title compound. This product was combined with the previously obtained precipitate and~e~ from toluene containing traces of MeOH to yield 4.5 g of the title compound.
ClsHloN2O2 . HCI
MP. = 297-301C
M.W. = 286.72 LR (KBr): 1705;1635; 1610 cm-l.
300 MHz lH-NMR (DMSO-d6): ~ 8.90 (d, 2H); 8.70 (m, 2El); 8.50 (s, 2H); 8.28 (d, lEI); 7.89 (dt, 2H).

wo ss/32s48 2 ~ 9 1 3 5 '2 r~
DESCRIPTlON 9 2 (q "~.;.lyl', - q: L ~ acid chloride h.~.l.. ' -1.3 ml (10.4 mmol) of oxalyl chloAde were dissolved in 60 ml of CH2C12. The 5 solution was cooled at -10C and 3.0 g (14.4 mmol) of 2-(4-pyridyl). ~ 4 carboxylic acid 1l.1V;~ were added ~JUIIiVll~ lC. The reaction mixture was left 72 hours at room i . and then evaporated to dryness to yield 4.0 g of the title compound, used without further L
ClsHgClN2O HCI
10 M.W. = 305.22 EXAMPLE~ 1 N-(~ ' y!' ,~ 2, ~lr, ' - q 15 1.2 ml (9.4 mmol) of (R,S) v-l_ ' Y1V~ L.Y- and 1.6 ml (11.7 mmol) of L.i~,lLJ- - CIEA) were dissolved, under nitrogen .- . in 50 ml of a 1:1 mixture of dry CH2C12 and CH3CN.
2.0 g (7.8 mmol) of 2-l' ~lc, ~' ~ 1 wlL,v..jl,,hlvli~e, dissolved in 50 ml of a1:4 mixture of dry CH2Ck and DMF, were added dropwise to the ice-cooled solution20 of the amines and the reacvion was kept at 0- 5C for 1 hour and left at room i . overnighL
The reaction mixture was evaporated rn-vacr o to dryness, the residue was dissolved in EtOAc amd washed twice with a saL sol. of NaHCO3. The organic layer was separated, dried over Na2S04, filtered and evaporated in-vacr(o to dryness.
25 The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound as a white solid.

M.P. = 156-157C
M.W. = 352.43 30 Elemental analysis: Calcd. C,8 1.79; H,5.72; N,7.95;
Foumd C,81.99; H,5.69; N,7.89.
LR. (KBr): 3240;1645 cm~l.
300 MHz IH-NMR (DMSO-d6): o 9 29 (d, lH); 8.32 (d, 2H); 8.13 (d, lH); 8.13 (s, lH); 8.06 (d, lH); 7.81 (ddd, lH); 7.68-7.52 (m, 4H); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd, lH); 5.30 (dq, IH); 1.52 (d, 3H).
MS (EI; source 200 C; 70 V; 200 mA): 352 (M+.); 337; 232; 204; 77.

wo 95132948 ; ~ 2 I q ~ 3 5 2 PCTIEP95/02000 ~(+~N-(~ 1)-2 ,' ,k, Prepared as Ex. 1 from 1.2 ml (9.4 mmol) of S-(-)-a. ~ , 1.6 ml (11.7 mmol) of TEA, 2.0 g (7.8 mmol) of 2-l' )'c, ' - 1 ~hu ~' '' ' in 100 ml of a mixture of CH2C12, CH3CN and DMF.
The work-up of the reaction mixture was ca~ied out in the same manner as described in Ex. 1. The residual oil was crystallized from EtOAc to yield 1.1 g of the title compound.

M.P. = 161-162C
M.W. = 352.43 [a]D20 = + 25 (C = 0.5, DMF) LR. (KBr): 3240;1645 cm~l.
300 MHz lH-NMR (DMSO-d6): o 9.29 (d, lH); 8.32 (d, 2H); g.l3 (d, lH); 8.13 (s, lH); 8.06 (d, IH); 7.81 (ddd, lH); 7.68-7.52 (m, 4EI); 7.47 (d, 2H); 7.39 (dd, 2H); 7.27 (dd, IH);
5.30 (dq, IH); 152 (d, 3H).
20 MS spactra was identical to that of the Ex. 1.

R~ N-( ',~ 2,' ,'~
Prepared as Ex. I from 1.2 ml (9.4 mmol) of R-(+)-a .~ , 1.6 ml (11.7 mmol) of TEA and 2.0 g (7.8 mmol) ûf 2-i .~lc, ~' 1 ~.u~u.. ~1.,;1u~in 100 ml of a mixture of CH2C12, CH3CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The residual oil was ~ from EtOAc to yield 1.1 g of the title compound.

M.P. = 158-160C
M W. = 352.43 []D20 = 25 (C = 05. DMF) LR. (KBr): 3240;1645 cm~1.
35 The lH-NMR and MS spectra were identical to those of the Ex. 1 and E~. 2.

wossl32948 1 219135? P~

(R,S)-N-t-( ' ~ l)berlzyl]-2 1- Jls 2.0 g (8.0 mmol) of 2-~ carbo~ylic acid were dissolved. under nitrogen ' A . in 130 ml of dry THF and 100 ml of CH3CN.
2.0 g (9.9 mmol) of (DL) methyl 1' .~ dlu-,l.lolidL and 1.5 ml (10.7 mmol) of TEA were added and the reaction mixture was cooled at 5C
2.5 g (12.1 mmol) of di~,~,' ' yl~ L ' '' (DCC), dissolYed in 10 ml of dry CH2C12, were added dropwise arld the solution was allowed to reach room , stirred for 5 hours and left overnight.
The r '~ ' ' ' ' d;.,, ' ' ~' was filtered off and the solution was evaporated in-vacuo to dryness. The residue was dissolved in CH2C12 and then washed with H20.
The organic layer was separated, dried over Na2S04 and evaporated in-vaalo to dryness to obtain 6.0 g of a crude product which was dissolved in 20 ml of CH2C12 and left overnight. Some more Ji.,~, ' ' ,y' ~ , ' and was filtered off.
The solution was evaporated in-vacuo to dryness and the residue flash ~ A on 230-400 mesh silica gel, eluting with a mi~:ture of l.~,~
acetate 3:2 containing 0.5% NH40H. The crude solid obtained was triturated with warm i-Pr20, filtered, washed and dried to yield 1.1 g of the title compound.

M P. = 170-172C
M. W. = 396.45 Elemental analysis: Calcd. C,75.74; H,5.09; N,7.07;
Found C,75.88; H,5.12; N,7.06.
LR (nujol): 3240;1750;1670 cm~l.
300 MHz lH-NMR (DMSO-d6): o 9.72 (d, lH); 8.28 (dd, 2H); 8.20 (dd, lH); 8.13 (dd, lH); 8.11 (s, lH); 7.83 (ddd, lH); 7.66 (ddd, IH); Z.60-7.50 (m, 5H); 7.47-7.37 (m, 3H); 5.78 (d, lH); 3.72 (s, 3H).
MS (EI; source 200 C; 70 V; 200 mA): 396 (M+.); 337; 232; 204.

~+)-(S)-N-[~-( " ~L yl)benzyl]-2 1~ ~l$ ' 1~

Wos~/32s4s ~ ~ ~ . 2 1 9 1 3 52 2.0 g (8.0 mmol) of 2-p~ ~X ' - 1 carboAylic acid were dissolved, under nitrogen atl~ ;.h/..r, in 70 ml of dry TEIF and 30 ml of CH3CN.
1.~ g (8.4 mmol) of (L) methyl 1 ~ y~ I.yL~hL~.de, 1.1 ml (9.9 mmol) of N-~ - ,'-" and 2.1 g (15.5 mmol) of N-;IJ~VA~ (HOBT) 5 were added and the reaaion mixture was cooled at 0C.
1.85 g (9.0 mmol) of DCC, dissolved in 10 ml of CH2C12, were added dropwise and the solution was kept at 0- 5C for 1 hour and then at room . for 2 hours.
The I , ' d;~ IO~ A~ was filtered off and the solution evaporated in-VQCUO to dryness. The residue was dissolved in CH2C12 and washed with H2O, SaL
10 soL NaHCO3, 5% citric acid, sat. sol. NaHCO3 and sat. sol. NaCl.
The organic layer was separated, dried over Na2SO4 and evaporated in-vacw to dryness; the residue was dissolved in 20 ml of CH2C12 and left overnight. Some more L~J. ~ and was filtered off.
The so~ution was evaporated in-vacuo to dryness to obtain 2.6 g of a crude produa 15 which was triturated with petroleum ether, filtered, washed with i-Pr20 and then recrystallized from 70 ml of i-PrOH to yield 1.7 g of the title compound.

M.P. = 180-181 C
M.W. = 396.45 20 LR. (nujol): 3300;1750;1640 cm~l.
[o]D20 = +42.0 (C = 0.5, MeOH).
The IH-NMR and MS spectra were identical to those of EA. 4.

25 (~ N-~a~ benzyl]-2-~' ,'S ~ ~ ~.. l ' Prepared as EX. 5 from 2.0 g (8.0 mmol) of 2-, ' JLI~.Jlil~c 1 carboAylic acid, 1.7 g (8.4 mmol) of (D) meth!yl ~' ~'",' hydrochloride, 1.1 ml (g.9 mmol) of N-~_~ . ' ' o, 2.1 g (15.5 mmol) of HOBT and 1.85g (9.0 mmol) of DCC in 70 30 ml of dry TE~ and 30 ml of CH3CN.
The worlc-up of the reacrion miAture was carried out in the same manner as described in EA. 5. The crude product obtained (3.5 g ) was triturated twice with warm i-Pr2O, filtered, washed and then lc~ lI;~d from 80 ml of i-PrOH to yield 2.3 g of the title compound.
35 C2sH20N2O3 M.P. = 180-181C
M.W. = 396.45 LR. (nujol): 3300; 1750;1640 cm~l.

W0 95132948 2 \ 9 ~ 3 5 ~ r~
[a]D20 = -42.0 (C = 0.5, MeOH).
The lH-NMR and MS spectra were identical to those of Exs. 4 and 5.

(R,~S)-N-[a-( ~' ~L ~I)benzyl]-7-me~oxy-2 ~L
1.0 g (5.0 mmol) of (I),L) meLhyl ~ 'g' h.r~u~hlu i~ were dissûlved, under nitrogen ~ ' . ' in 30 ml of dry DMF.
2.5 g (IS.1 mmol) of anhydrous potassium carbonate were added arld the solution cooled at 0C.
0.7 g (2.3 mmol) ûf Lhe compound of Description 3, dissolved in 25 ml of dry DMF, were added dropwise and the solution was kept at 0- 5C for I hour and at room I , overnighL
The reaction mixture was evaporated in-Yacuo to dryness and the residue was dissolved in EtOAc and washed twice with H2O. The organic layer was æparated, dried over Na2S04, filtered and evaporated zrz-vacuo to dryness.
The residual oil was flash, ' ,, , ' ' on 230-400 mesh silica gel, eluting with a rni~ture of I '~1 acetate 3:2 containing 0.5% NH40H to afford 0.1 g of the crude product which was triturated with z-Pr2O to yield 0.08 g of tne title compound.

M.P. = 187-190C
M W. = 426A8 LR (KBr): 3220; 1750; 1660; 1620 cm~l.
300 MHz lH-NMR (CDC13): o: 8.13-8.08 (m, 3H); 7.80 (s, lH); 7.55-7.38 (m, 9H);
7.21 (dd, lH); 7.02 (d broad, H); 5.88 (d, lH); 3.97 (s,3H); 3.80 (s, 3H).
MS (EI; source 200 CC; 70 V; 200 mA): 426 (M+.); 367; 262; 234; lgl;77.

(R,S)-N-[a-( '' ,~L ~I)benzyl]-7 hydroxy 2 ~' ,'c~ ' '' ~
Prepared as Ex. 5 from 2.1 g (5.3 mmol) of the compound of D~s~lirtiz~n 4, 1.08 g ~5.3 mmol) of (D,L) meLhyl ~ LI~J.il~, 1.5 ml (10.7 mmol) of TEA, 1.7 g (12.5 mmol) of HOBT and 1.2 g (5.8 mmol) of DCC in 70 ml of dry TE~-and 30 ml of CH3CN.
The work-up of Lhe reaction mixture was carried out in Lhe same manner as described . . . ~

Wo gs/32948 ~ ~ r~
in Ex. 5. The crude product obtained was triturated with i-Pr20 and then ~lli~l twice from i-PrOH to yield 0.06 g of the title compound.

M.P. = 256-257C
5 M.W. = 412.45 LR. (KBr): 3270; 1750;1650;1620 cm~l.00 MHz lH-NMR (DMSO-d6): ~ 10.30 (s broad, IH); 9.64 (d, lH); 8.æ (d, 2H);
8.04 (d, lH); 7.85 (s, lH); 7.60-7.34 (m, 9H);
7.21 (dd, lEI); 5.74 (d, IH); 3.71 (s, 3H).
MS (E~I; source 200 C; 70 V; 200 mA): 412 (M+.); 353; 248; æo; 77.

(R,S)-N.ta-~ l].7.methoxy 2 ,p' ,'-, ' q:
~.,~ ' ' ' 0.18 g (0.4 mmol) of the product of Ex. 7 were dissolved in 10 ml of 109~a ElCI and 5 ml of dioxane. The reaction mixture was refluxed and stirred for 3 hours, then eYaporated in-vacuo to dryness.
The crude product was triturated with warm EtOAc (cont~ining a few drops of EtOH) to yield 0.16 g of the title compound.
C25H20N204.HCI
M.P. = 228-230C
M.W. =448.91 IR. (KBr): 3180; 1~35;1655;1630 cm~l.
300 MHz IH-NMR (DMSO-d6): ~ 9.6 (d, IH); 8.26 (dd, 2H); 8.14 (d, lH); 7.98 (s, lEI); 7.63-7.52 (m, 6EI); 7.46-7.36 (m, 3H); 7.33 (dd, lH); 5.66 (d, IH); 3.98 (s, 3H).
MS (EI; source 200 C; 70 V; 200 mA): 412 (M+.); 368; 262; 234; 191; 77.

(R,S)-N-[(~ yl)benzyl]-2 ~ , ' q ~
0.45 g (1.1 mmol) of the product of Ex. 4 were dissolved in 40 ml of 33%
MeNH21EtOH; a catalitic amount of NaCN was added and the reaction mixture was heated at 70C for I hour in a parr apparatus. The internal pressure rised to 40 psi.
The soluùon w3s evaporaoed in-vacuo to dryness and the residue was triturated with waoer, filoered, dried and .~ ~lI;~d from a mixture of i-PrOH (50 ml) and EtOH
(30 ml) to yield 0.2 g of the title compound.

~ r';, i ~
W095B2948 2 1 9 1 3 5 2 P~~

M.P. = 261-263C
M.W. = 395.47 Elemental analysis: C:~lcd~ C,75.93; H,5.35; N,10.63;
S Found C,75.65; H,5.34; N,10.55.
IR. (KBr): 3300; 3270:1660;1635 cm~1.
300 MHz lH-NMR (DMSO-d6): ~ 9.48 (d, lH); 8.33-8.25 (m, 3H); 8.18-8.10 (m, 3H); 7.80 (ddd, lEl); 7.68-7.50 (m, 6H); 7.40-7.28 (m, 3H); 5.75 (d, lH); 2.63 (d,3H).
MS (El; source 200 C; 70 V; 200 mA): 395 (M+.); 337; 232; 204; 77.

(R,S)-N-[a-( ~ ~ L ~I)benzyl]-2-(~ienyl`, - 1- 1, ' Prepared as Ex. 5 from 2.0 g (7.3 mmol) of 2-(2-thienyl)~ r-' ~ 1 carboxylic acid, 1.7 g (8.4 mmol) of (D,L) methyl ~ h.~ lu~hlt, 1.1 ml (10 mmol) of N ` ~' . ' ' 2.1 g (155 mmol) of HOBT and 1.85 g (9.0 mmol) of DCC in 70 ml of dry THF, 30 ml of CH3CN and 10 ml of CH2C12 The work-up of the reaction mixture was carried out in the same manner as described 20 in Ex. 5. The crude product obtained was crystallized from EtOAc and tben l~ ~D~lli~d from abs. EtOH to yield 0.9 g of tbe title compound.

M.P. = 178-180C
M.W. = 402.47 Elemental an:~lysis: Calcd. C,68.64; H,4.51; N,6.96;
Found C,67.50; H,4.99; N,7.43.
LR. (KBr): 3300;1745;1645 cm~l.
300 MHz lH-NMR (DMSO-d6): o 9.70 (d, lH); 8.12 (d, lH); 8.08 (s, l~I); 8.04 (d, lH); 8.02 (d, lH); 7.19 (t, lH); 7.76 (d, IH);
7.62 (t, lH); 7.53 (d, 2H); 7.46-7.37 (m, 3H); 7.3 (dd, lH); 5.68 (d, lH); 3.68 (s, 3H).
MS (El; source 200 C; 70 V; 200 mA): 402 (M+.); 343; 238; 210; 77.

lR,S)-N-[~-( ' .~ I)benzyl]-~(2-furyl). ' " f ~I '' Prepared as Ex. 1 from 7.2 g (35.5 mmol) of (D,L) metbyl 1' ~1"' Ly~ 12.4 ml (88.8 mmûl) of TEA and 9.1 g (35.5 mmol) of crude 2-(2-. _ ~

.~ 2 1 9 1 3 5 2 WO 95B2948 ` ( `~ l ~ -' I ., I/r,l ;. . ::
furyl)S ' 1~ ' '' ' in 350 ml of a mixture of CH2C12, C1313CN and DMF. The work-up of the reaction mixture was carried out in the same manner as described in Ex. 1. The crude product obtained waD triturated with MeOH to yield 3.3 g of the title compound.

M.P. = 178-180C
M.W. = 3g6.405 Elemental analysis: Calcd. C,71.49; H,4.70; N,7.25;
Found C,71.67; H,4.74; N,7.17.
10 LR. (KBr): 3300; 1750;1650 cm~l.
300 MHz lH-NMR ~DMSO-d6): ~ 9.72 (d, lEl); 8,12 (d, lH); 8.06 (d, lH); 7.96 (dd,lH); 7.92 (s, lH); 7.80 (ddd, lH); 7.62 (ddd, lH); 7.52 (dd. 2H); 7.45-7.35 (m~ 4H); 6.73 (dd, lH); 5.77 (d, lH); 3.74 (s, 3H).
MS (EI; source 200 C; 70 V; 200 mA): 386 (M+.); 327; 222; 194; 77.

(R,S)-N-[a-( ' ~' Jl)benzyl]-2 (q rJ~ q 20 Prepared as Ex. 1 from 3.4 g (16.7 mmol) of (D,L) methyl ~
hJLV~ i~, 3.9 ml (27.8 mmol) of TEA and 3.0 g (11.1 mmol) of 2-(4-pyridyl) . ~ b~JIlJ' ' ' ' ' in 100 ml of a mix~ure of CH2C12, CH3CN and DMF. The worl~-up of the reaction mixture was carried out i~ ,he same marJner aDdescribed in Ex. 1. The crude product obtained was l~DIall;~d tbree times from EtOAc to yield l.g g of the title compound.
C24Hl9N303 M.P. = 172-174C
M.W. = 397.43 Elemental analysis: Calcd. C,72.53; H,4.82; N,10.57;
Found C,71.87; H,4.87; N,10.44.
IR. (KBr): 3240; 1750;1670 cm-l.
300 MHz lH-NMR (DMSO-d6): o 9.74 (d, lH); 8.79 (dd, 2H); 8.27-8.17 (m, 5H);
7.89 (ddd, lH); 7.74 (ddd, lH); 7.54 (dd, 2H);
7.47-7.38 (m, 3H); 5.8 (d, lH); 3.75 (s, 3H).
MS (El; source 200 C; 70 V; 200 mA): 397 (M+.); 338; 233; 205; 77.
EXAMP.,E 14 (R,S)-N.[o~ ~L ~I)-2 ~ ]-2 ,' ,lq ' q w0 ssl32s4s 2 1 9 1 3 5 2 r ~
Prepared as Ex. 1 from 1.94 g (9 4 mmol) of (D,L) methyl ' Jl~-~, '' ' . 2.7 ml (19.5 mmol) of TEA and 2.0 g (7.8 mmol) of 2-S ~ c~ ' ~ ccubu~ u i~ in 100 ml of a mixture of CH2C12, CH3CN andDMF. The work-up of the reaction mixture was carried out in the same manner as described im Ex. 1. The crude product obtained was ~ D~Ili~l tbree timeD from EtOAc to yield 0.66 g of the title compoumd.

10 M P. = 144-145C
M.W. = 402.47 Elemental analysis: Calcd. C.68.64; H,4.51; N,6.96;
Found C,68.81; H,4.46; N,6.96.
IR. (KBr): 3295; 1745; 1640 cm~l.
300 MHz lH-NMR (CDC13): ~ 8.25 (dd, IH); 8.22 (dd, IH); 8.17 (dd, 2H); 7.95 (s, IH): 7.78 (ddd, IH); 7.60 (ddd, IH); 7.5~7.45 (m.
3H), 7.35 (dd,lH); 7.20 (d, IH); 7.05 (dd, IH); 7.~5 (s broad, IH); 6.22 (d, IH); 3.9 (s, 3H).
MS (EI; source 200 C; 70 V; 200 mA): 402 (M+.); 343; 232; 204.

(R,S)-N-t~ yl)benzyl]-2 ~ - 4 ~' Prepared as Ex. S from 139 g (5.60 mmol) of 2-~ c, ' 1 carboxylic acid, 1.2 g (5.60 mmol) of (R,S) methyl 3-amino-3-~ h~.' '' ' 0.78 ml (5.60 mmol ) of TEA, 1.51 g (11.2 mmol) of HOBT and 2.31 g (11.2 mmol) of DCC in 10 ml of dry THF, 4 ml of CH3CN and 7 ml of CH2C12. The wo~k-up of the reaction mixture was carried out in the same marmer as described in Ex. 5. The crude product obtained was dissolved in CH2C12 and left at 0C overnight. Some more 30 di~ ' L . ' and was filtered off.
The solution was evaporated in-vacuo to dryness to obtain 1.4 g of a crude product which was triturated with a mixture of i-Pr2O/acetone 99:1 to yield 1.2 g of the title compound as a white solid.

35 M P. = 156-158C
M.W. = 410.47 Elemental analysis: Calcd. C,76.07; H,5.40; N,6.82;
Found C,75.77; H,5.38; N,6.94.

w095132948 ,~ 21 91 352 r~
LR. (KBr): 3295; 1755; 1645; 1590; 1530 cm~l.
300 MHz lH-NMR (DMSO-d6): ~ 9.40 (d, lH); 8.29 (dd, 2H); 8.14 (d, lH); 8.07 (d, lH); 8.04 (s, lE~); 7.83 (ddd, lH); 7.66-7.52 (m, 4H); 7.50 (d, 2H); 7.40 (dd, 2~); 7.31 (ddd, lH);
5.60 (dL IH); 3.65 (s, 3H); 3.04-2.89 (m, 2H).
MS (~I; source 200 C; 70 V; 200 mA): 410 (M+.); 337; 233; 205.

W095132948 ` ' ` ` 2 1 9 1 3~2 r~
o ~ R ~
~ ~ o ~ -- -- o r o ~ o o ~ V~ x r ~ ~ ~ X O O O ~ X ' X ~ ~ ~
V ~
O O O O O O O O O ~ O O ~ O ~
r ~ ~ ~ ~ ~ _ ~ ~ X X ~ x "
~~ V V V V V V ~ V ~ ~J V V ~ V
G--' G~ G' * ~ ~ ~ ~ Y Y Y
G--Z ~ . "
2 ~ ~, y ~ ~ ~ = !r = ' y !r ~ ~. :C
Z O O O

WO 95/32948 ~ , 2 1 9 1 3 5 2 F~~ - lt- --~ U~ X 1l' ~ cei e _ _ e L~, v ~ ~
~ ~ `O
S ' ~
C~ ~ . ~
~ s ~ t C C . - ~
~ ~ ~ . ~ +
s ~ci _i C~ _ '~
; s .' ~ . ~ ~
-- ~Z ~ ~Z
~ 50 --- ~ Z~ ;~rl Z"
ei . ~ , a-~ ~z ~z ~z ~ ~ --i X

, , . . . . :

W095132948 ~ , 21 q 1352 r ~
=
~o o o o~
+
c , ~ K ~
_ ~ O
3 ~ v~ ~ ~ ~
~D X
C` ,~ ~ C C
~q ~ ~ ~ _ Y
TN N TN =N ~N
_ ~e ~ ~ e ~,~e ~e X ~ O -- ~

WO 95/32948 ~ p~ l/r.l ~- --~
O ^
U ~, C o C ~ C o~ = -- C
o _ X
~O ~ ~i ~ x C1;~, G ~
~, _ _ ~ _ _ G~ G ~ G
T : ~Z, T
-o~ ~ 0~ ~Z ~Z
O ~ X

WO 95/32948 " ~ 2 ~ 9 1 3 5 2 r~ ~
o o C~
V ~, = X ~ C U) ~ ~ X ~ X ~=
X ~o ~ X
t X ~ o X
3 ~o o o o o O ~ x ~ ~
o o o~ ~ o E , ~
o --~ o ~ ~ o ~ -- -- -- U~
C~ ~ y C~
~C ~
8 ~ 8 ~8 I
, ~oo~ ~ o~ ~ o~z o ~

W095/32948 i ~ , 21 91 352 r~
o ~i ~ cr, O ~ ~
~ ~o~ c~
C`~
3 C`~ o ~ X ~;
E
o ~
~ Lâ U~
~ C~ Y
o~ z _ ~-` ~8 ~
T
~Z o~ ~ o~ 0~
~O ~ X
C~ C', ~ Cl-) .

wogs/32948 ; 2 ~ 91352 r~
o o ~. Il ~O
~ ~ , X ~ ~ _ C
E ~ ~
~v ~e ~o _ ;~; O~ ~
oo V~ ~ ~ ~t Xo J ~ `t 't o ;`~ O t ' ' O
O-- ~ V~ _ Y
E~ 8 z z,, z" z~ z ~o ~ ~ ~

.

WO 95/32948 ~ 2 1 9 1 3 5 2 T ~
~,, O
E ~ ~ ` ~~ o ~ :~
W
~, ~ X o ' E Z Z~
Y ~q =~ Z
8 ~ T
s e ~ c .

W095/32948 2 ~ q 1 352 r~l,r~
o O
o U
O ~ X
C , X K ~_ S
~ ~
~ O~
g .
0 _ V~
-.~ O ~ O~Z
~ X 0'1 1` i` .,; 2191352 ---wo 95~32948 P~~
Y
o ,~, O
: ~, o _ _ . ~ C~
- . æ E ~ , y X
~~ o x ~,, ~ 1;, _ C~ ~ '' ~ o o ._ ~
3 Y . C` E Y Z -~
t c ~ -. ~ ~ o Q
. Y .
~ ~o~ ~
' c E = ~ 8 ~8 - 8~z 8-~ 8 ~ e~ C . o U~ ~

W095132948 2 1 9 1 352 P ~ 7 ~
-V ~ ~ ~ ~r~ X ~ v~ ~ O
~ ~ ~ o ~ ~
3 ~ ~ ~ v~
X o ~ ~
t -~ Z ~' ~
V V V
V~ V~ V~ V~
~ ~ Y ~:
e T ~ T
0 ~ z ~z `i 219~352 W0 95~32948 ' I F~~ ,3,'~
o O
_I ~
E t ~_ ~ ~ X ~ ~ Q
X O~ t-- ~o 3 ~ ` ~t x :E ~ o t~ It ~-`1 ~ .--1 .
c~ E ~
~ o ~ o C~ ~
~, ~ _ _ _ _ ~8 ~ c ~8 ~8 T

t~ ~ 0_~ T_~
t.-- X cr~ O

W0 95132948 2 ~ 9 1 3 5 2 r ~
~
a ` ~ ~ _ Q ~ o~
_ ~ ~," O ~,, o O O o u~--~ ~ ~0 ~
E ~0~8 ~8 ~
T

~z o~ _~
~ ~o `D `D ~D

W0 9S/32948 `~ i , 2 1 q ~ 3 ~ 2 r~
,~ o ~, C
E ~ _ o C~ ~o C~ c~
~ ~ o ~
-X X ~ ~
o ~ ~ o .
S U

8 ~g ~ c @ 0~2 0_~ o_~ 8~
X ~ ~o ~` ~Xo C -WO9~/32948 ~ 1 9 ~ 352 r~

~ ~ ~D ~ ~ l ~
u -- -- O 1 ~ 5 K C~ o -- ~ X X ~0 ~ t--2 _ 8 ~ x ~D
C o~
. _ ~ ~j L
; ~ 3 '~ _ _ _ ~ V~
U~
~ ~ r,,~ e ~1 T = z T~ 0~ T
_ ~ ~

W0 95/32948 2 ~ 9 ~ 3 5 2 r~

o~o +
C _ _ _ _ _ _ _ s _ s s _ æ ~ O
Z
~, ~3 =-~z~ o z ~ T T
T 0 ~ T _~
k't ,~ `D ~` x ; 2~91352 WO95132948 F~11r.l 5,~ -~, O
V ~c, e ~ e x e J O
Z ~
o ~ ,,, ~ ~
E -I _, Z ~
~ V U
V~
4 ~ T
8 ~ ~8 T =N Z
8~
Cl~ X X

wo gs/32948 r~
O ,~
X o <~
~ +
o~' ~ ~ ~ o ~ -- _ , _ ~ a~ ~ ~ ~
X
3 x ,,, ~
X ~ ~ X
E o ~
: ~
b~
O ~
o~z o~Z o~z o~z T o o x ~ ~ u~
ci~ x x x x 2~91352 ~ wO gsl32948 ` r~
~ _ _ o ~ _ _ O ~ O ~ O S o -- O
E ~ ~ ~ ~ ~ ~ r ~ ~ o ~o ~ ~ c 3 ~
c 3 ~ ,,, " ~ ~
~ o~ ~ , o C
~ ~ = o ~ E ' o ~ _ o E ~
~8 ~Z~ cco;
=Z ~ T~ ~ ~0 ~
o~ o~ ~ E
- ~S 8 ~ Z~
-- O~
_ O O
E ~Z '~ r,~ .
'c.
x x E-W0 95~32948 ' ~ O o V~
.
o ~ o = ~ o o ~3 o ~ o ,, ~ ~ ~ ~o o~
~ ~ V~ oo - o X ~
C C ~ O
. _ .~ .? .
1/ ~ t E
~ ~ Y X lY
T ~ T
~ u 8 ~ 8 . 8 - ~Z
;i;~ ~ -- ~`I

W095/32948 ~ 2 ~ 9 1 3 ~2 P~ , r--,~6 @~ '6;
_ r~ ~ _ r` ~î ~ ~ E E a ~, E ~~
-- x c æ ~ cr~ C'' 'r . c~l O v, ~ ~ o~ ~ ~ ` C~
c~ ~ ~ r~ ~ 0~ E r~ -- C'' r~ c~ o ~ r~ E E
~ C~ _ g C ~ + C
O c~` O r r~
r~
x r c~î ~ r ~o '~ Ft ô u~ ~
t C ~ ~ ` e IY C~ `D ~ ~ ~ ~ C ~ ~ ~ ~ ` _ u~
~ ~ ~t r~ o ~ x ~ u-~
o o ~c o-~ ~ ~
r~ r~ r~ r~
g~ C ~c c r r 1.~ u~
9 _- - ~^ o c t~ ~ cr~ r~ ~D ~ c ~t x E r~ r~ r~ r~ x x r~ r~
~, æ ~ æ ~, æ
t~ ~D r~ x o~ o ~ _ _ _ _ c~

WO9S/32948 ~ ; f ~) ii; 21 91352 r~

~ ~ ~O ~ ~ ~ ~ ~ ~ .c ~ E ~D ~ ~ ~ `D E x r ~ v~ ~
._ x x ~ yO ~, o ~ ~ ~D ~ I` o o__- _^ ~. ~
;c. -- _ o~ ,~ ~ _ +
x ~ ~
' $
E .. .. ..
~~ V
i:l o o o ~ ô u~ ~i o o yr ~ ~ x ;~ ~
r ~ ~ ~~ $ ~ c ~C ~D r ~ r r ~ ~
VZ Z Z Z Z Z Z Z Z Z Z Z.
` r o v~
5 5 5 5 5 5 5 5 5 5' 5 5 ~ x o o~ o x ~ x _ ~
E~x ~x` x x ri -- 'r'7 ~ ~x x ri C.l V ~ r U ~ , r~ r~
c~ ~ c ~ ~ c ~ c rl ~ ~

.

WO9S/32948 21 q 35 r~

~^ W ~ O - ~ o ~ ~ ~
W ~ t _ X ~ Cl~ D ~ X O X _ ~ o _ C-oo o r~ X X
~ ~ ~ ~ ~` ~D ~ ~D^ ~
8 o ~,,^ r--^ ~` -- --^ -- --^
_ C~ + +
~ ~ X ;- o ~ o o o o ~, . . . . . . . . ~ .
~t t'l o~
ô ~ ô ô ô ~- o ~ o o o o y V~ X ~o t~ ~ t~ ~o ~ X t^~ ~o V~ o t,, _ t~, _ ~, _ ~ _ _ ~ _ ~ _ _ t-, _ _ _ t~ ~ X ~C t'~ ~- t~ t~ X
~ ~ X o t~ t~ I ~ C X
a Z Z Z~ Z~ Z Z ~D r ~ ~ `D
t~ ~` t '~ ~O O ~ ;O ~ 1~ t~ ` O
O~ I C O ~ ~' ~ ~ ~ ~ ~t V ~C ~O ~ V` `O ~ ~ ~ V~ ~
e: 5~ 5 5 5 5` 5 5 5 5 5 5 5 5 5'-o ~ ~ o X o, X ~ X t o~ CC X X X X ~ X X
~ U ~ U ~ ~ U U U ~ U ~
C~ t~ t~ t~ ~ t~ ~ t~ =
U U L ~ U ~LO U~ u æ u~
x ~ x t~ O
~, ~ t~, t~ t~ t~ t wo 95/32948 `"';~ 9 1 3 5 2 r~

s , ~ U
, 0o ;~ ~ ~ + + !r + _ ~ a ~o ~
~`I O X ~ O ~ ~ 5 X~ ~ X 5~ _ E. .. ....
'^~ ~ ~ ~ ~ ~D
o ~ o o o o o o o o Y ~ 5 ~ 1-- ~ ~r ~ 0 5~ ~
o ~ o ~ ~ ~ o C` O
r ~ ~ ~ x aZ Z Z Z Z Z Z Z Z; Z Z Z
;~~ x ~n ;~ o ~I `D 5 ~ ~ C 5 ~:5 5 3 5~ 5^ 5, 5 5 5 5 3 3 X5 t-- ~ ~ X 1 2~X 0~ 5; 0 ~ ~D C~ t`~ C`~ C`~ ~`.
X X X X t--_ ~ -- o ~ O ~ ~
X~~ ~O 1` X 5 2 9~3 2 wo gsr32948 1 5 r~ r 0 ~ ~ ~ ô
8 ~ $
E ~ ~ ô ô ô ô ,,^ ~' o ~ ~ ~ O ~ O O O O O
~D O ~^ c~ --O

r~O~ ~ _ O O c~
-- 5 5 5 ~ 5 o, 5 r~ 5' ~ 5 5 ~ 5 5` 5 -E x x ~ o ~ ~ ~ ~ x x ~,~ D ~ 2 x ~ ~t ~ ~

2~91352 wo 95/32948 P~~
W ~~ ~ -- , ~ o -- . ' ~ o ~ ~ X

o ~ ê ~ e ~ 0 ~ o~ ~ x . ~ O~ O ~ O
'' ~ ~ ~ ~0 . ~
æ ~ æ ~ xæ æ
80 ~ æ ~- X-~ c + + + + ~r +
~ O ~
O ~o ~ O _ ~
E
. ~ ~ o ~. o o o U~ o o ~ o o o ô
~ o o o o o o o o o V~ o o o o o o o ~ o~ o ~ ~ V~ ~ V~ ~ ~ V~
~., _ _ ~., _ ~ _ ~ _ _ _ _ ~ _ _ ~, _ _ O O _ O ~ ~0 ~ ~ ~ V
r ~ Z Z Z Z Z Z Z Z Z Z Z ~ Z
~ ~ ~ X ~D ~D, ~ ~ v v~ V~ V~ V V
S ~,. -- ~ O ~ r o _ ,~ rl ~D `O
æ ~ , 2 ~ 2 ~ ~
K ~ X ~ V~ V~ V~
\~

-;~, 2191352 ~W0 9SM2948 P~ [
~ 3 ~' X _ X ~, a ,- _ ~ _ ~ ~ x ,~ x ~^ = x . ~
E ~ E ~ ~ S ~ _ ~ ~. O ~ S
--r~ E ~ ~ ~ ~ ~ o~ E ~ .
._ ~ .
~o e ~ " ~ E ~; O
~ r ~ ~ ~r '`I ~
~ ~ - y~ - - - - - - - -y o o o g IY~ ~ `O ~ 7 `D v~ ~ v~ ~ v~ ~ ~ V~
o~ - ~ x ~ ~ o o x ~
O C` O O
z~ z z z z z z z z z V~ V~
^ 'T ~ T
CO C7~ 0 X ~ ~ I O
~ U U U ~ U U U U V U
G o G O U ~ U G o X
C~

2 1 9 ~ 3 5 2 wo 9~132948 w ~ ~ ~ ~ ~ ~ _~ o O ~ w ~ X ~ ~ ~ ~ -- X ~ -- X ~ ~ -- O -- ~ X ~
â _ ~ ~,~^ ~ ~r E o- _ E _ q _ ~ E ~ _ ~ V~ ~a _ !r o~ ~ ~ E ~ o ~ o _ ~ o~ o ~r ~ ~ o ~ ~
.^ ~ o X
V ~- o ~ ~
Y ~ ~ o _ ~ X
~ _ -- _ _ -- _ _ _ ~ I` C~î O `D ~^ ~ ~
E *
~ O O o ~ O O O O O o O O V~ O
L ~o V~ O ~ V~ D V~ ~D V~
Y ~V~ ~ ~ V ~ CV~ ~`I V~ O V~
O~ ~ C~` I` X ~ O~ O~ V~ ~' x r v~ V
U Z Z Z Z Z Z ` ~ ~ ~
æ G ~ , O ~ ~ X X ~ V 1~
2 ~ ~ u~ v. v. v.
5 5~ 5, 'r 5~ 5~ 5 ~ 5, 5~ 5 5 C V~ ~ --^ ~ X ~ ~ ^
~ ~ ~ ~ i ~ ~ o o C X X 1~ ~ X~ X~
~ C ~ ~ ~ = ~ = ~ = ~ C
c~ 2 v ~ c, ~ ~ ~ ~, ~L v ~
~ x~ ~ ~ ~ ~

wo gs/32948 ' r~ 7 C ~ E ~ E ~ ~ ' ~ c ~ --G e O ~ ~ ~ . O c D _ ~ D ~ -- ~ X o _ O
_ _ ~ o _ c7~ OX~ ~ ~ E ~ r~ ~. -- ~ ~ ~ E o .~ ~ ~ ..
~o o~
o ~ ~ ~ ~ o - ~^
., o _^ - ~o' ~' '`` ~' U~ o U- ~"
~ _ r ~:3 o ~ o ~ + x ~o ~ x x ~- ~ ~ o x ~
-. ~ ô ~ ô o ô ~ ô ~ ô ô
e~ r ex~ ~oo y ~ o~ o~ g~ g~ g^ ô o~ ~ o o $ ~oc, ~ ~ ~ o =~i r r' r r ` -- o . ~ Z. Z~ O ~ Xô ô
~O ~ C ~'~ o ^
X `i `i `i r ~ ~= r X
3 ~ ~ ~
$ o ~o ~ ~X

wogsl32948 ' 2 1 9 ~ 352 r o ~ o, ~ 5 ~ 5 --5 ;~ 5' ~ ~ X l_ o ~ ~ ~ ~o ~ ~ ~ ~ - ~ ~
,~ E o~ E ~,~ ~ E E ~ ~ ,_ E o~ E '` o E
V _ o ~ 0 ~ ~ ~
æ ~ ~ U~ U~ ~ uO, ~
O -- _ ~ ~ . ~^ ~^
j~ . ~0 +
O X O _ , ~'' ~ =
--u O^ c^ ^ ~^ ~ ~^ ~ ~^ ^
O O O U~ O O Ul O O O O
y ~ uj ~ u~ ~ ~ u~ ~ ~ ~ u` X U U
-- ~ -- r~ 7 -- r~ _ ~ _ c ~ cr ~ r~ u~ r C'`
r r~ r r~
Z z z z, Z Z Z; Z Z Z; Z Z.
~ ~ r~ ~ ~ O ~ c g ~I u~
cu ~ s~l ~ sl ~ ~ 5 X s, s 5 5 s' E `I ~ r` ~ r ' c~ ~i ` ~ ~ o ~^ ~I
c~ r` r ^ `D v v v v v v v v v ~ ~ v ~ v ~ v ~ v ~
x o -- ~ ~ ~
r~ r~ r~ r~ r~ r \~58 wo 95/32948 P~~

~ _ ~ ~ O ~_ ~ O X ~r ~ o ~ ~ ~c1 ~ ~
., x E ~ ~ o ~ o x ~ ~
._ ~
t ~ A ~ ~
~ ~ ~ . . ~
L~^ + + + C~ -- +
~~ S~ ~ X ~ V~
el~ `D U~ O U~ ~ ~D -- U~ r- ~ ~ ~ u~ ~ u~
^ ~ ~O X ~ `O ~ -- ~,o ~ ~ ~ U~ ~ ~~ ~ ~D U~
~: o~ - ~ o ~ ~
~ u~u~ u ~ ~ ~ o g Vl 7` Z` Z` Z Z Z Z Z Z Z Z Z Z Z
-- ~ U U~ ~ ~` O ~ X X ~ O O ~ô
;" U ~ ~t ~ ~ X o~ X ~ ~ U; C'` `
5 55~ 5' 5' ~ 5' 5 5, 5, 5. 5, 5' 5~
- - _ U~ ~ ~ ô ~ ~
u~ U~ ~ ~ X ~ V~
X X -- --e ~ U ~ ) O U
~, æ ~ O ~ ~0 ~ C c ~ ~~ X ~, X X X

2~91352 WO 95132948 P~l/r.l ,.,' :
S ~ C
S S ~ 3^ é ~ 5 ~ S o ~ é
x E ~ x E ~ x ~ -- x 'I= ~ --g ~ r ~ r- ~; x^ e~
y oo ~ ~ o ~ g ~ - - x x - o~ o ~t - - - - - - - - - - - - - --- X ~ ~ ~ ~ ~ ~ ~ ~ CVI~ ~ VO
~i O ~ V- ~ ~ ~'~ ` '`'' V V ~o ~D
z z~ z z- z z z- z- z ~ z z z z ~ oo o~ x x ~ x c~
~ O ~ X V', V~ Vi V~ Vl V~ c V ~
5~ ~ 'T ~ 5, 5 ~ 5 = 5 5 5 ~ 3:
5~ X U . U ~ ~,, X X X X ~ '`i X X ~D V
U U U V U U U U U U U U U U
~' u æ u IL u æ u æ v æ v æ
~ X X V~ `X X X X

wo 95~32948 2 1 9 1 3 5 2 P~l/h~
X ~ X _ ~ X !T~
- ~, !r ~ ~`' 3 7- -- --x X ~ x ~." " E x ~o X ~ o -- -- !r ~ -- ~^ ` X -- --o X ~ ~ X ~ ~ ~, X ~ ~
~ !r X a ~,^ ~ E !T. --~ E
.~, _ ~_ E ~ _ ,_ ~ -- ~ ~ -- ~ ~D -- ~' O _ ~ J
O
~ _ ~O ~ ~
X
~:.
._ ô ô O o O O '~
O O O O O O U~ O
Y ~ ~o ~D ~ ~ ~ ~ 'I' ~ _ _ ~ _ _ _ _ C X. ~C ,,, O' iô
_ O', O~ ~o C ~ O` t-- ~ O
x ~ x O
C'~ _ ~ ~ A
~ O _ ~ O
1;1 ~ ~ ~ *

WO 9sB2s48 r ~ ` 2 ~ 9 1 3 5 2 (R,S)-N-[-(M~ ~L ,I)benzyl]-2-(p :' ' . ,' yl~ , ' ' -1 2 g (7.0 mmol) of 2-(p-.,lllolu,ul.ellyl`, ~' ~ 1 carboxylic acid and 1.7 ml (15.4 mmol) of N-me~ ,nl: ,~ were dissolved, under rlitrogen ' I ,1 ' . in 50 ml of dry THF.
The sûlution was cooled to -20C and 0.91 ml (7.0 mmol) of isobutyl ~,hlul~ ' were added. After 20 minutes, 2.12 g (10.5 mmol) of methyl (R,S) 1~ E,lyl ll,~u~,Llulhle and 1.3 ml (11.9 mmol) of N ,~ ,' ' . dissolved in 30 ml of dry THF, were added and the readon mixture was stirred at room t.. ~ .,.r overrlight.
5 ml of H20 were added and the reaclion mixtllre was evaporated in vacuo to dry~ess. The residue was dissolved ir Et2O, washed with a saturated solution of NaHCO3, æparated, dried over Na2SO4 and evaporated in vacuo to dryness.
The residual oil was flash, h ~ . ' ~' on 230-400 mesh silica gel, eluting with a mixture of 1,.,,. ~/;sv,ulu~ l ether 7: 3 to afford 0.9 g of crude product, which was recrystallized three times with iPrO21toluene to yield 0.5 g of the title compound.
C25Hl9ClN2o3 M.P. = 170-172 C
M.W. = 430.90 Elemental analysis: Calcd. C, 69.72; H, 4.45; N, 6.50 Fourd C, 69.82; H, 4.47; N, 6.48 IR. (KBr): 3280; 1740;1670; 1635;1590;1530 cm~l.
300 MHz lH-NMR (DMSO-d6): 9.71 (d, lH); 8.32 (d, 2H); 8.21 (d, lH); 8.13 (d, lEI); g.l3 (s, lH); 7.85 (dd, lH); 7.67 (dd, lH);
7.63 (d, 2H); 7.~3 (dd, 2H); 7.46-7.38 (m, 3H);
5.79 (d, IH); 3.74 (s, 3H).
MS (EI; source 200 C;70 eV; 200 IIA): 430 (M+.); 371; 266; 238; 203.

(R)-N-[a-(~ ~L ,1)1 ' ~; ~1]-2 1' ~ls ~. .~
0.62 g (1.5 mrnol) of (R)-N-[o~ hu,-r.,~l,ullyl)~ll,ydlvAyv~ l]-2-lrlS ~linP /I-CA~ i ~ (compound of Ex 83) were dissolved in 30 ml of dry acetone and 2 ml of dty DMF; 0.14 g (0.75 mmol) of R2CO3 were added and the reaction mixture was stirred for 30 minutes.
0.093 ml (1.5 mmol) of methyl iodide were added at rvom ~...II...AlI r and the reaction mixture was heated at 40 C for 4 hours. 0.104 g (0.75 mmol) of K2CO3 and wo 9sl3zg48 ` 2 1 9 1 3 5 2 0.093 ml (15 mmol) of methyl iodide were added again. and the mixture refluxed for additional 6 hours.
The mrxture was evaporaoed in vacuo to dryness, dissolved in EtOAc and washed with H2O. The organic layer, dried over Na2SO4, was evaporated in vacuo to dryness. The residue was recrystallized from Et2O to yield 0.45 g of the title compound.
C26HæN204 M.P. = 160-162 C
M.W. = 426.48 Elemental analysis: Calcd. C, 73.22; H, 5.20; N, 6.57 Found C, 73.01; H, 5.20; N, 6.48 LR. (KBr): 3210; 1750;1635; 1625; 1590; 1530;1515 cm~l 300 MEIz lH-NMR (DMSO-d6): 9.65 (d, lH); 8.28 (d, 2H); 8.21 (d, lH); 8.14 (d, lH); 8.10 (s, lH); 7.84 (dd, lH); 7.67 (dd, lH);
7.61-7.49 (m, 3H); 7.44 (d, 2H); 6.98 (d, 2H);
4.70 (d, lH); 3.7g (s, 3H); 3.76 (s, 3H).
MS (EI; source 200 C;70 eV; 200 ~ 426 (M+.); 367; 232; 204.

(R,S)-N-[a-(M~ ~.; ,I)-a-(methyl)benzyl]-N-me~yl-2 ~
0.50 g (1.3 mmol) of (R,S~-N-Ia-( ' yl ~b~ yl)benzyl]-2-~' ~'S ~' (compound of Ex. 4) were dissolved, under nilrogen ~ ~ , ' , in 10 ml of dry DMF.
The solution was cooled to 0 C and 0.052 g (1.3 mmol) of NaH (60%) were added;
after 20 minutes at 0 C the I , was raised to r.t. and 0.09 ml (1.4 mmol) of MeI were added. The reation mixture was stirred at room t~ r I overnight, then the procedure was repeated by adding additional 0.052 g (1.3 mmol) of NaH (60%) and 0.1 ml (1.6 mmol) of MeI.
After 6 hours at room i . . 10 rnl of saturated solution of NH4CI were added and the reaction mrxture was evaporated in vaCuo to dryness. The residue was dissolved in CH2C12 and washed with water, the organic layer was separated, dried over Na2SO4 and evaporaoed in vacuo to dryness.
The residual oii was flash ~,hl~ 7 1~ ' ' on 230400 mesh silica gel, eluting witb a mixture of L~.~.c~'~ l acetate 3: 2 corltaining 0.5% of conc. NH40H to afford 0.18 g of a crude product which was dissolved in Et20 and treaoed with HCI/Et20 to yield 0.15 g of the title compound.
C27H24N203.HCI
M.W. = 460.96 wo 9sl32s48 2 1 9 1 3 5 2 I.R (KB}): 1745; 1640;1610 cm~1.
MS (EI; source 200 C;70 eV; 200 IzA): 424 (M~.); 365; 232; 204.

(R,S)-N-[~ l)benzyl]-2 ~ 15 ' " q ~i ' 0.27 ml (3.1 mmol) of oxalyl chloride were dissolved. under nitrogen ' , , in 2.3 ml of dry CH2C12 The solution was cooled to -55 C and 0.22 ml (3.1 mmol) of DMSO, dissolved in 0.7 ml of dry CH2C12, were added dropwise ' ~ the temperature below -50 C. The reaction was stirred at -55C fol 7 minutes then 0.97 g (2.5 mmol) of (R,S)-N-[-(1-ll,yd~u~ l)benzyl]-2-~ luu~.lolu.~ l ' (compound of Ex.
17), dissolved in 25 ml of dry CH2C12, were added keeping the: . between -50 and -55 C.
After 30 n~inutes at -55 C, 19 ml (13.6 mmol) of TEA were added without exceeding -40 C, then the reaction mixture was allowed to reach room:
and stirred for additional 15 minutes.
The reaction was quenched with 5 ml of H2O and extracted with CH2C12; the organic layer was washed with H2O, 20% citric acid, saturated solution of NaHCO3 and brine; the organic layer was separated, dried over Na2S04 and evaporated in vacl~o to dryness.
The residual oil was flash c lu~ ~, . ' on 230-400 mesh silica gel, eluting with a mixture of ~ ; acelate 70: 30 containing 0.5% of conc. NH40H to afford 0.64 g of a crude product which was triturated with warm i-Pr2Oti-PrOH 2: 1, filtered, washed and dried to yield 0.5 g of the title compound.

M.P. = 160-161 C
M.W. = 380.45 Elemental analysis: Calcd. C, 78.93; H, 5.30; N, 7.36;
FoundC,79.01;H,5.31;N,7.27.
IR. (KBr): 3400; 3265; 1725; 1660;1640;1592 cm~l.
300 MHz lH-NMR (DMSO-d6): 9.60 (d, lH); 8.29 (d, 2H); 8.17 (d, lH); 8.14 (d, lH); 8.12 (s, 1~); 7.82 (dd, lH); 7.65 (dd, lH);
7.61-7.51 (m, 5H); 7.48-7.36 (m, 3H); 2.19 (s, 3H).
MS (EI; source 200 C;70 eV; 200 ~LA): 380 (M+.); 337; 232; 204.

(R,S)-N-[a-(2-11,~.~.A,~.,lh.,l)benzyl]-2 ~ '5 '' 1~' 0.7 g (1.7 mmol) of (R,S)-N-[-(~ u~ .~bu.. ~ llyl)benzyl]-2-1 ,~1c, ~' -woss/32s4s ~ ' ` 2 1 9 ~ 35~ r 4 ~ , rlr (compound of Ex. 15) were dissolved, under nitrogen r~ in 50 ml of t-BuOH and 2 ml of MeOH.
60 mg (1.6 mmol) of NaBH4 were added in 15 minutes to the boiling solution. The reaction mixture was refluxed for 6 hours, quenched with 5 ml of saturaled solution of NH4CI ar~d therl evaporated in vacuo to dryness. The residue was dissolved inCH2C12 arld washed with brine; the organic layer was separated, dried over Na2SO4 ~md evaporated in vacuo to dryness.
The crude product was ~ash ~1.., ,,, ' on 230-400 mesh silica gel, eluting with Et20 contaming 0.5% of conc. NH40H and then crystallized from i-PrOH to yield 0.19 g of the dtle compound.

M.P. = 167-169 C
M.W. = 382.47 Elemerltal analysis: Calcd. C, 7852; H, 5.80; N, 7.32;
Found C, 78.4g; H, 5.79; N, 7.29.
I.R. (KBr): 3360; 1650; 1592 cm~l.00 MHz lH-NMR (DMSO-d6): 9.30 (d, IH); 8.31 (d, 2H); 8.13 (d, lH); 8.10 (s, lH); 8.03 (d, lH); 7.81 (dd, lH); 7.64-7.51 (m, 4H); 7.46 (d, 2H); 7.39 (dd, 2H); 7.29 (dd, lH);
5.30 (dt, lH); 4.61 (t, IH); 3.61-3.41 (m, 2H);
2.11-1.86 (m, 2H).
MS (EI; source 200 C;70 eV; 200 I~A): 382 (M+.); 337; 232; 204.
EXAMPLE g8 (S)-~-(a-Ethylbenz~ (2 !'' '' .~ q ~L ' 1,.~1" ~. ..
0.62 g (1.6 mmol) of (S)-N-(a ~ I~.~yl)-3-hydroxy-2-p~ .o.. e~
P (compound of E~ 85) were dissolved in 30 ml of dry DMF.
0.58 g (4.0 mmol) of ~ ' ~I~.fl..u~ lllo.id~ I~Lu~,LhJlidr and 0.56 g (4.0 mmol) of K2CO3 were added and the reaction mixture was refluxed for 20 hours.
The K2CO3 was filtered off and the mi~ture was evaporated in Yacuo to dryness, dissolved in AcOEt and washed with H2O and with 20% citric acid. The aqueous layer was made aLIcaline with 2 N NaOH and e~traced with EtOAc; the organic layer was washed with brine, separaed, dried over Na2SO4 and evaporaed in vacuo to dryness.
The residue was flash ~ " .' ' on 230-400 mesh silica gel, eluting with CH2C12/MeOH 98: 2 containing 0.4% of conc. NH40H and then with CH2C12/MeOH 86: 10 containing 0.6% of conc. NH40H to yield 85 mg of a crude producl which was dissolved in EtOAc and treaed with HCI/Et20 to obtain 75 mg of wo g5/32g48 f; ~ 2 ~ q 1 3 5 2 I ~
tbe title compound.
C29H31N32 HCl M.P. = 70 C dec.
M.W. = 490.05 IR. (nujol): 3600; 3100;1650;1550 cm~l00 MHz IH-NMR (DMSO-d6): 10.28 (s br, lH); 9 50 (d, lH); 8.10 (d, lH); 7.96 (dd, 2H); 7.78 (m, IH); 7.67-7.61 (m, 2EI); 7.61-7.51 (m, 3H); 7.49-7.39 (m, 4H); 7.33 (dd, lH);
5.08 (dt, lH); 3.90 (t, 2H); 2.96 (dt, 2H); 2.49 (s, 6H); 1.85 (m, 2H); 0.97 (L 3H).
MS (FAB POS, Ll~iogly~ ul matrix, Xe gas, 8 KeV, source 50 C): 454 (MH+) (S)-N-(~-EII..,'' .~1)-3-a~ 2,' .,`~
0.40 g (1.05 mmol) of (S)-N-(c~ yl)-3-amino-2-l~h~,.l.~lq ~
(compound of ~x. 69) were heaoed in 25 ml of acetic anhydlide at 70 C
for 1 hour and then at 100 C for additional 3 hours.
The reaction mixture was then evaporated in Yacuo to dryness and the residue dissolved in EtOAc; the solution was washed with water, saturaud solution of NaHCO3, brine, dried over Na2SO4 and evaporated in vacuo to dryness The crude product (0.39 g) was purified by silica gel flash column .,l.~
eluting with a mixture of hexane/EtOAc/conc. NH40H, 70: 30: 0.5, I~DYe~ to afford 0.2 g of a pure compound which was I~ DIalli~d from acetone to yield 0.14g of the tide compound.

M.P. = 268-269 C
M.W. = 423.52 Elemental analysis: Calcd. C, 76.57; H, 5.95; N, 9.92;
Foumd C, 76.38; H, 5.98; N, 9.90.
LR. (Br): 3230;1670;1640;1555;1525 cm~l.00 MHz lH-NMR (DMSO-d6): 9.65 (s, lH); 9.05 (d, lH); 8.10 (d, lH); 7.80 (t, lH); 7.70-7.50 (m, 4H); 7.45-7.20 (m, 8H); 5.08 (dt, lH); ~.g5 (m, 2H); 1.60 (s, 3H); l).g7 (t, 3H).
MS (EI; source 200 C;70 eV; 200 IlA): 423 (M+.); 3gl; 334; 289; 261; 247; 218.

WO9s/32s48 ' 21 91 352 r~

(-)-(S)-N-(a-Ethylbenzyl)-3-(3 ~ h,~
L2 g (3.1 mmol) of (-)-(S~-N-(a-ethylbenzyl)-3-hydroxy-2-pl~
(compound of Ex. 85) were dissolved in 15 ml of dry THF.
1.0 g (8.2 mmol) of 3- i;~ d~u~ JlcLlu~idc, dissolYed in 10 ml of Et20, 1.3 g (9.4 mmol) of R2C03 and 0.16 g of Rl were added and the reaction mi~ture was sbrred at room '~ I' , ' ~ for 30 minutes and then refluxed for 2 hours.
Further 0.77 g (6.3 mmol), 1.0 g (8.2 mmol), û.6 g (4.9 mmol) and addidonal 0.6 g (4.9 mmol) of 3-I- ~ , ,"~cLluIhlc, dissolved each time in 10 ml of Et20, and some RI were added every 12 hours and the reactdon refluxed.
The K2C03 was filtered off and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H2O and with 20% citric acid. The aqueous layer was made aL~aline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to dryness.
The residue was nash , O, ' on 230-400 mesh silica gel, eludng with CH2C12/MeOH 95: 5 containing 0.5% of conc. NH40H to yield 0.9 g of a crude product which was dissolved in EtOAc and treated with HCI/Et20 to obtain 0.62 g of the dtle compound.
C30H33N302.HCI
M P. = 108C dec.
M.W. = 504.08 [a]r~20 = - 16.0 (c = 0.5, MeOH) LR. (KBr): 3400; 3080; 1655; 1545 cm~l.00 MHz IH-NMR (DMSO-d6): ~ 10.55 ~s br. IH); 9.35 (d, lH); 8.09 (d, lH); 7.92 (dd, 2H); 7.76 (ddd. lH); 7.65-7.51 (m, 5H); 7.48-7.40 (m, 4H); 7.31 (dd, lH); 5.10 (dt, lH); 3.72-3.62 (m, 2H); 2.75-2.60 (m, 2H); 2.58 (d, 3H); 2.56 (d, 3H); 1.90-1.67 (m, 4H); 1.00 (t, 3H).
MS (EI; source 180 C; 70 V; 200 mA): 467 (M+.); 466; 395; 58.

(-)-(S)-N-(a-EthJ;L ~1)-3-[2~ phthaloylkthoxy]-2 ~ ' ,',t, ' 1 ~ L ' h~
19 g (5.0 mmol) of (-)-(S)-N-(a-ethylbenzyl)-3-hydroxy-2-i' yl~lui~ c-4-.- I,..,,; 1~ (compound of Ex. 85) were dissolved in 20 ml of dry THF.

woss/32s4s ~ 2 ~ 91352 r~
3.8 g (14.9 mmol~ of 2-rht~ v~ c, dissolved in 15 ml of THF, 2.0 g (14.~ mmol) of K2C03 and 0.25 g of KI were added and the reaction mixture was stirred at room , for 2.5 hours and then refluxed for 2 hours.
l.g g (7.4 mmol) of 2-~ lbromide and some Kl were added and the reaction was refluxed for additional 3.5 hours.
0.5 g (2.0 mmol) of 2 ,' 1 ~Ib~u~l~lJc and some KI were added again and the mixture was refluxed for 5 hours.
The K2C03 was filtered off and the mixture was evaporated in-vaCW to dryness, dissolved in CH2C12 and washed with H20. The or,~anic layer was dried over Na2S04 and evaporated in-vacuo to dryness.
The residue was flash ', ,~ .' 1 on 230-400 mesh silica gel, eluting with hexane/EtOAc 80: 20 contairling 0.5% of conc. NH40H and vhen hexane/EtOAc 60:
40 containing 0.5% of corlc. NH40H to afford 2.6 g of a purified product which was triturated with iPr2O to yield 2.5 g of the title compound.

M P. = 172-175C
M.W. = 555.64 [C~D20 = - 16.3 (c = 0.5, MeOH) LR (KBr): 3280; 3060; 2960;1780;1715; 1660;1530 cm~l.00 MHz IH-NMR (DMSO-d6): o 9.27 (d, lH); 8.03 (d, lH); 7.92-7.84 (m, 4H);
7.78-7.69 (m, 3H); 7.60-7.53 (m, 2H); 7.46-7.38 (m, 4H); 7.27 (dd, lH); 7.13-7.04 (m, 3H); 4.96 (dt, lH); 3.92-3.78 (m, 2H); 3.72-3.55 (m, 2EI); 1.78 (dq, 2H); 0.93 (t, 3H).
MS (EI; source 180 C; 70 V; 200 mA): 555 (M+.), 526, 421, 174.

(-)-(S)-N-(~-E~ '' ,1)-3-(2-. ' ' J)-2 ~ 1 ~L
~.~L ~
2.2 g (3.9 mmol) of (-)-(S)-N-(a L.llJll,~..L~.~3-[2-(1-phthaloyl)ethoxy]-2-phenyl rA '- ~ dl. 1 ' (compound of Ex. 101) were dissolved in 150 ml of 96% EtOH and 0.38 ml ,'7.8 mmol) of hydrazine hydrate were added to the boiling solution, which was then refluxed for 4 hours.
Further 0.4 ml (8.2 mmol), 0.2 ml (4.1 mmol), 0.2 ml (4.1 mmol), 0.4 ml (8.2 mmol) and 0 4 ml (8.2 mmol) of hydrazine hydrate were added every 12 hours and the reaction mixture was maintained refluxed.
The reaction mixture was then evaporated ~n-vaC~0 to dryness, dissolved in 20 mlH2O, cooled and acidified with 10 ml conc. HCI.

Wo ss/32948 ~ ! 2 ~ 9 1 3 5 2 P~~
The mixture was boiled for I hour and cooled; the phthalydrazide was filtered off.
The aqueous layer was washed with EtOAc and then made alkaline with 2 N NaOH
and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vac~lo to dryness.
The residue was flash ~ grarhPA on 230-400 mesh silica gel, eluting with EtOAc/MeOH 96: 4 containing 1.2% of conc. NH40H to afford a purified product which was dissolved in EtOAc and treated with HCI/Et20 to yield 1.2 g of the title compound.
C27H27N3o2 M.P. = 119C dec.
M.W. = 462.00 [O']r,20 = - 19.4 (c = 0.5, MeOH) I.R (KBr): 3400; 3080; 1640;1545 cm~1.
300 MHz 1H-NMR (DMSO-d6): ~ 9.45 (d, lH); 8.09 (d, lH); 8.00 (dd, lH); 7.94 (s br, 3H); 7.76 (ddd, lH); 7.65-7.51 (m, 4H); 7.48-7.40 (m, 3H); 7.31 (dd, IH); 5.09 (dt, IH); 3.83 (t, 2H); 2.72 (m, 2H); 1.93-1.80 (m, 2H); 0.99 (t, 3H).
MS (FAB POS, Llliogl~.,c.ul matrix; Xe gas, 8 keV; source 50 C): 426 (MH+).

(+)-(S)-N-(c~-Elh~ ..~1)-3-[2-(1-~J. ~ I)ethoxy]-2 ~ ' -q ~.;. ' h,~J.. ' ' ' 2.0 g (5.2 mmol) of (-)-(S)-N-(o~-ethylben~yl)-3-hydroxy-2-pl-~-,,y1q -' - 1 h11. ,AP (compound of Ex. 85) were dissolved in 25 ml of dry THF.
1.0 g (7.5 mmol) of 2-pyrrolidi-1v~,L~ ~lcl-lulide and 2.2 g (15.9 mmol) of K2C03 were added and the reaction mixture was stirred at room i , for 30 minutes and then refluxed; 1.1 g (8.2 mmol) of 2-pyrrolidinoethylchloride were added to the 30 boiling solution which was Rfluxed overnight.
The K2CO3 was filtered oflf and the mixture was evaporated in-vacuo to dryness, dissolved in EtOAc and washed with H2O and 20% citric acid. The aqueous layer was made alkaline with 2 N NaOH and extracted with EtOAc; the organic layer was washed with brine, separated, dried over Na2SO4 and evaporated in-vacuo to 35 dryness.
The residue was flash ,1.., - ~graphPd on 230-400 mesh silica gel, eluting with - CH2C~21MeOH 97: 3 containing 0.5% of conc. NH40H to yield 1.8 g of a purifled product which was dissolved in EtOAc nnd treated with HCI/Et20 to yield 2.0 g ofthe title compound.

Wo 95132948 ~ 1 9 1 3 5 2 PCT/EP9~02000 M.P. = 110-115 C (dec.) M.W. = 516.08 ~a]D2~ = + 4.5 (c = 0.5, MeOH) LR (KBr): 3400; 3080;1655; 1545 cm~l.00 MHz lH-NMR (DMSO-d6): ~ 10.50 (s br. IH); 9.50 (d, lH); 8.10 (d. lH); 7.96 (dd, 2H); 7.78 (ddd, lH); 7.68-7.30 (m, 10H); 5.10 (dt, lH); 3.90 (m, 2H); 3.20 (m, 2H); 3.00 (m, 2H);
2.65 (m, 2H); 1.95-1.65 (m, 6H); 1.94 (t, 3E~).
S (EI; source 180 C; 70 V; 200 mA): 479 (M+.); 478; 383; 97; 84.

(S)-N-(a-F ' ~'' .1)-3-( ' ' J` ~ 2 ~ q ~; ' 1.1 g (2.8 mmol) of (-)-(S)-N-(a-~a~ .. ~1)-3-amino-2-yl-~ ;-4-. -.I,....- ;.l~ (compound of Ex. 69) were dissolYed, under nitrogen _ , ' , in 10 ml of warm toluene. 0.96 g (5.6 mmol) of chloroacetic anhydride, dissolved in 5 ml of toluene, were dropped and the solution was refluxed for 1 hour.
The reaction mixture was evaporated in-vacuo to dryness, suspended in 10 ml of CH2Ck and dropped in 5 ml of ice-cooled 28% Me2NH/EtOH.
The solution was stirred at room , overnight, then 15 ml of 28%
Me2NH/EtOH were added and the reaction mixture was heated at 60 C in a parr apparatus.
The mixture was evaporated in-vacw to dryness, dissolved im 20% citric acid and washed with EtOAc. The aqueous layer was basified with 2 N NaOH and e~tracted with EtOAc; the organic layer was washed with brine. separated, dried over Na2SO4 and evaporated in-vaCuo to dryness to afford 1.4 g of the crude product This product was triturated with warm i-Pr20 to yield 0.86 g of the title compound.

M P. = 189-191 C
M.W. = 466.59 [~X]D20 = _ 63.1 (c = 0.5, MeOH) LR. (KBr): 3230; 3180;1670;1630;1540 cm~l.00 MHz lH-NMR (DMSO-d6): ~ 9.41 (s, lH); 8.97 (d, lH), 8.08 (d, lH); 7.81 (dd, lH); 7.70-7.59 (m, 4H); 7.49-7.26 (m, 8H); 5.00 (dt, lH); 2.55 (s, 2H); 1.97 (s, 3H); 1.90-1.65 (m, 2H); 0.93 (t, 3H).
MS (EI; source 180 C; 70 V; 200 mA): 466 (M+.); 331; 58.

` 2191352 WO 95/32948 ~ ` ' PCT/EP95/02000 N-(,-DiL.._LLyll,_~yl)-3-hydro~y-2~p~- ~yl4u-lloline-4-~b~
2.0 g (7.5 mmol) of 3-hydro~y-2-phenylqll;nAliAr 1 ~bw~ylic acid were dissolved, under nitrogen ~ h ~, in 70 r.~l of dry THF and 30 rnl of CH3CN.
1.02 g (7.5 mmol) of ~u~yla~e and 1.12 g (8.3 mmol) of N-Lyulu~ylJ~,. ..I ,Ai..le (HOBT) were added and the reaction rn~ ture was cooled at -10C.
1.71 g (8.3 mmol) of DCC, dissolved in 20 r~l of CH2C12, were added dr. pwise and the solution was kept at -5- 0C for 2 hours and then at roûm ~ , è overrlight. The lu,~ lûh_AyLue~l was filtered off and the sûlution _.~l~ulaLI d in-uacuo to dryness. The residue WâS dissolved in CH2C12 and washed with lI2O, sat. 501. NaHC03, 5%
citric acid, sat. sol. NaHCO3 and brine.
The organic layer was ser~t~l dried over Na2SO4 ana ~.al~ulaL~ ~ in-vacuo to dryyness; the residue was dissolved in 20 ml ûf CH2C12 and left e,vernight. Some more dicycloh_.-ylu~ u~_i,uiL~L_~ and was filtered off.
Al'he solutiûn was ~ ~,uu, ~.bi in-uacuû to dry-ness to obtain 1.4 g ûf a crude product which was flash ~L.""A~ hA~I on 230-400 mesh silica gel, eluting initially with he~anelEtOAc 9/1 and then he~ane/EtOAc 8/2 to afford 0.4 g of the purified product which was recrystalli2ed twice from i-PrOH to yield 0.15 g of the title ~ l"J" ~

M.P. = 166-169C dec.
M.W. = 382.47 I.R. (nujol): 3200;1650;1580;1535 cm~1.
300 MHz lH-NMR (DMSO-d6): o 9.56 (s, IH); 8.92 (s br, IH); 8.00-7.94 (m, 3H); 7.76 (d br, IH); 7.63-7.45 (m, 7H); 7.36 (dd;
2H); 7.24 (dd, lH); 1.72 (s, 6H).
MS OEI; source 180 C; 70 V; 200 mA): 382 (I~+.); 264; 247; 219;119.

N-(a,-I~ ' ~Ibenzyl)-3-arnino-2-pl.e.lylq.... nl~
2.0 g (7.6 rnmol) of 3-aminû-2-phenylquinoline-4-carbo~ylic acid were dissolved, under nitrûgen i~Lll~u~luh~ in 70 rnl of dry l~' and 30 rnl of CH3CN.
7l W09s/32948 '~ ' 2 1 9 1 352 P~
1.02 g (7.6 mmol) of cumylamine and 1.12 g (8.3 mmol) of N-Lyv~u~yl~ ^ (HOBT) were added and the reaction mi~ture was cooled at -10C.
1.72 g (8.3 mmol) of DCC, dissolved in 20 ml of CH2Cl2, were added dropwise and the solution was kept at -5- 0C for 2 hours and then at room ~ .c overnight. The ~I~_i,v;L~Lc~ vi~y~lOh~ylulc~L was filtered off and the solution ~ v ~Lc~ in-vacuo to dryness. The residue was dissolved in CH2C12 and washed with H20, sat. sol. NaHC03, 6%
citric acid, sat. sol. NaHCO3 and brine.
The organic layer was 5Pr~r~rPrl~ dried over Na2SO4 and cv~l~vl~:L_l in-vacuo to dryyness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more vi~ loh~ylulc~ ~.. ~;LdL~ I and was filtered off.
The solution was c ~, l,v.~.LI d in-vacuo to dryness to obtain 2.0 g of a crude product which was flash ~ A on 230-400 mesh silica gel, eluting with he~anelEtOAc 6/4 "~ 1% of conc. NH40H to afford 0.9 g of the purified product which was recrystallized from he~anelEtOAc 1/1 and then from i-PrOH to yield 0.45 g of the title r-~

M P. = 166-168C
M.W. = 381.48 I.R. (nujol): 3460; 3360; 3220;1667;1605;1527 cm~1.
300 MH2 lH-NMR (DMSO-d6): o 9.05 (s, IH); 7.87 (dd, lH); 7.74-7.68 (m, 3H);
7.60-7.42 (m, 7H); 7.37 (dd, 2H); 7.24 ~dd, lH);
4.74 (s, 2H); 1.71 (s,6EI).
MS OEI; source 180 C; 70 V; 200 mA): 381 (M+.); 263; 218; l l9.

(-)-(S)-N-(v-EthylbeIlzyl)-5 ''~, ~1-2 pL~yL~
0.80 g (3.04 mmol) of 5-methyl-2-ph ..y~ n~ vv~.ylic acid were dissolved, under nitrogen ~ c, in 30 ml of dry 'l'~l~' and 12 ml of CH3CN.
0.43 g (3.20 mmol) of (S)-(-)-o~-ethylbc~yl~iue and 0.78 g (5.78 mmol) of N-hy~lv~yh....~ (HOBT) were added and the reaction mi~ture was cooled at-10C.
0.69 g (3.34 mmol) of DCC, dissolved in 5 ml of CH2Cl2, were added dropwise and the solution was kept at -5- 0C for 2 hours and then at w09sl32948 2 19 35 r~
room L~Lu,u~ Lule overnight. The !~Le~u;L~LLed dicyclol;c~ylul~3d was filtered off and the solution ~ u~ ed in-vacuo to dryness. The residue was dissolved in CH2Cl2 and washed with H2O, sat. sol. NaHCO3, 5%
citric acid, sat. sol. NaHCO3 and brine.
The organic layer was s~r~r~t~l dried over Na2SO4 and c~a~ul~d in-vûCuo to dryness; the residue was dissolved in 10 ml of CH2Cl2 ard left overnight. Some more dicyclohexylurea ,u.~ ;L~ L. d and was filtered off.
The solution was ovc~.pu~LL~d in-vacuo to dryness to ûbtain 1.16 g ûf a crude product which was flash ~LLu-LulLu~ d on 230-400 mesh silica gel, eluting with he~ane/EtOAc 6/2 cnnt~in;n~ 0.5% of conc. NH40H to afford 0.47 g ûf the purified product which was recrystallized from i-Pr2O
~nntslinin~ some drops of EtOAc to yield 0.36 g of the title cmnro~ln~ as a white pûwder.

M.P. = 189-192 C
M.W. = 380.49 [a]D23 = 3.8 (c = 0.5, MeOH) LR. (Br): 3280; 3070; 3020;1635;1545 cm~l.
300 MHz lH-NMR (DMSO-d6): 8 9.20 (d, lH); 8.23 (d, 2H); 7.93 (d, IH);
7.78 (s, lH); 7.20-7.70 (m, 10H); 5.00 (dt, lH); 2.38 (s broad, 3H); 1.70-1.90 (m, 2H);
0.95 (t, 3H).
MS OEI; source 180 C; 70 V; 200 rnA): 380 (M+.); 246; 218.

(R,S)-N-[~ ~v,~_Ll,yl)benzyl]-3 ~yl-a-r' ~ ~oli~e-4-~L ' Prepared as described in E~. 1, starting from 11.08 g ( 3g.33 mrnol) ofcrude 3-methyl-2-pheny~ innlin~-4-wLLbullylcLloride~ 4.87 g (32.20 mmûl) of l-phenyl-2-hydLuJ~yl~lu,u~l~ille and 10.33 ml (74.14 mmol) of TEA in 150 rnl of a 1:1 mixture of dry CH2C12 and CH3CN.
The ~ æd TEA hydrochloride was filtered off and the filtrate in-uacuo to dryness; the residue was dissolved in CH2C12 (100 rnl) and washed with a sat. sol. of NaHCO3, 20 % citric acid and brine. The organic solution was dried over Na2S04 and ~ v~uul~ d in-VQCUO to dryness to obtain 13.23 g of an oil, which was cryst llized from i-Pr02 (100 ml) rnnt~inine 6 ml of i-PrOH to yield 9.14 g of the title wo 95l32948 ; ~ - r . 2 1 9 1 3 5 2 r~~
cnnnrollntl as an off-white solid.

M P. = 163-165 C
M.W. = 396.49 LR. (nujol): 3400; 3260;1635;1580 cm~1.
E~AMPLE 109 (R,S)-N-[a~ yl~,~l,~.,~yl)benzyl]-3 ' ~1-2 ,' yl ~.~L ~
Prepared as desc~ibed in E~ample 96, starting from 3.25 g (25.60 mmol) of o~alyl chloride, 3.88 g (49.66 mmol) of DMSO, 8.2 g (20.68 mmol) of (R,S)-N-[a-(1-Lyd,u,.~ ~Lyl)benzyl]-3-methyl-2-ph~ u, loline ~ . ,1, .. _ ". =l~
(compound of E~. 108) and 15.72 ml (112.76 mmol) of TEA in 230 ml of dry CH2cl2-The reaction was quenched with 40 ml of H2O and the organic layers~r~r~tPd and washed with 20% citric acid, sat. sol. NaHCO3 and brine.
The organic solution was dried over Na2S04 and ~ u.L.L- d i~-vac~o to dr~ness to afford 9.4 g of the crude title l-nnnrolln~ as an oil. This residual oil was flash ~L.. ~ P~ on 230-400 mesh silica gel, eluting with a mi~cture of he2cane/ethyl acetate 70: 30 ~ e 1% of conc. N~40H to afford 7.7 g of the purified product which was crystallized from a mi~ture of EtOAc/he~ane 1: 3 ,.~ ly, to yield 6.0 g of the pure title nnnnro~ln~ ~

M P. = 156-158 C
M.W. = 394.48 LR. (nujol): 3270; 3180;1735;1725;1660;1630;1527;1460 cm~1.
300 MHz 1H-NMR (DMSO-d6): o 9.53 (d, IH); 8.01 (d, IH); 7.73 (dd, lH);
7.62-7.35 (m, 12H); 5.97 (d, lH); 2.30 (s br. 3H);
2.18 (s, 3H).
MS (EI; source 180 C; 70 V; 200 mA): 394 (M+.); 352; 351; 246; 218; 217.

(R,S).N-[a-(Ethyl)-4-pyri~' ' yl]-2-rl ~14~Gl;.
~ .Y. ;Ar 4.12 g (16.52 m}nol) of 2-phenylquinoline-4-carboxylic acid were dissolved, woss/32s48 ` ; 2 1 9 1 3 52 ~ c under nitrogen ~t7nnsrhPre~ in 40 ml of dry CH2C12 and 30 ml of THF.
1.50 g (11.01 mmol) of 1-(4-pyridyl)-n-propyl amine and 2.23 g (16.52 mmol) of N-IIYd1UA.~b~7 ;~ le (HOBT) were added and the reaction mixture was cooled at 0C.
3.41 g ( 16.52 mmol) of DCC, dis601ved in 26 ml of dry CH2C12, were added dropwise and the solution was kept at 0C for 2 hours and ther. stirred at room ~ for 36 hours. The ~ u;~ d di~ lùk~ Aylulta was filtered off and the solution e ~alJu~aLe~ in-vacuû to dryyness. The residue was dissolved in 100 ml of CH2C12 and washed with H20, 10% K2C03, 5% citric acid and brine.
The organic layer was serArAt~-l, dried ûver Na2S04 arld L~a~uu,.lL. 1 in-vacuo to dry~ess; the residue was dissûlved in 30 ml of CH2C12 and left overnight. Some more di~ lùh~Ayl~ a ~u~ , ' and was filtered off.
The 601ution was o .a,uu.aLed in-vac~û to dryness to obtain 3.5 g of a crude product wkich was recrystallized three times from i-PrOH to yield 0.91 g of the title ~n~nrolln~

M.P. = 218-219 C
M W. = 367.45 LR. (KBr): 3260; 3060;1648;15g5; 1545;1350 cm~l.00 MHz lH-NMR (DMSO-d6): o 9.33 (d. IH); 8.58 (d. 2H); 8.33 (dd. 2H); 8.15 (d. IH); 8.14 (s. lH); 8.03 (d. IH); 7.82 (dd. IH);
7.66-7.52 (m, 4H); 7.47 (d, 2H); 5.05 (dt. IH); 1.85 (dq, 2H); 1.00 (t. 3H).
MS (EI; source 180 C; 70 V; 200 mA): 367 (M+.); 338; 232; 204.

(R,S)-N-to~-OEthyl)-2-Ll~ ' ~1]-2-ph~ hluLuoline.4-1.40 g (8.00 mmol) of 1-(2-thienyl)-n-propyl amine hydrochloride and 2.45 ml (17.60 mmol) of TEA were dissolved, under nitrogen Af~nnsFh~re, in 50 ml of dry CH2C12 and 30 ml of CH3CN.
2.0 g (8.00 mmol) of 2-ph~.,ylu,uil.olille-4-carboylic acid and 1.30 g (9.60 mmol) of N-llyLu,.~l-.l ..~ . ;,. ..1~ (HOBT) were added.
2.48 g (12.00 mmol) of DCC, dissolved in 30 ml of dry CH2C12, were added dropwise and the sûlution was stirred at room ~ for 36 hours.

2 I q 1 3 5 2 wo 95132948 P~ ~/L'.I . ~
50 rnl of 10% HCl were added and the solution stirred for aditional 2 hours. The ~ LL~d dicyclohesy-lurea was filtered off and the organic layer washed with 10% citric acid and 10% K2CO3.
The organic layer was l3r~zlrslr~rl~ dried over Na2SO4 and e~a~ d in-UQCUO to dryness. The crude product was fla6h cLL~ k~ on 230-400 mesh silica gel, eluting with a misture of he~ane/EtOAc!CH2Cl2 80:
15: 0.5 to afford 2.0 g of a yellow oil which was crystallized from a misture of toluene/hesane to yield 0.9 g of the pure title compound as white crystals.

M.P. = 134-137 C
M.W. = 372.49 IR. (KBr): 3230; 3060;1630;1690;1545 cm~1.00 MHz 1H-NMR (DMSO-d6): o 9.33 (d, lH); 8.30 (dd. 2H); 8.15 (d, IH); 8.13 (d, lH); 8.08 (s, IH); 7.84 (ddd, lH); 7.68-7.51 (m, 4H); 7.44 (dd, lH); 7.11 (d, lH); 7.02 (dd, lH);
533 (dt, lH); 2.10-1.88 (m, 2H); 1.05 (t, 3H).
MS (EI; source 180 5C; 70 V; 200 mA): 372 (M+.); 343; 232; 204.

(S)-N-(c~-Ellly~. ~.,~1)-3--' ~ - '~1-2-~h~ u~oli~ 4-~,~1 -' I-,~,L~>- 1.1". :A~
5.60 g (21.27 rnmol) of 3-methyl-2-phenyl~ui~oli~c I carbo~ylic acid were dissolved in 100 rnl of dichloroethane.
7.60 g (42.50 rnmol) of N~ and 0.52 g (2.00 mmol) of dibenzoyl peroside were added and the solution reflused for 24 hours.
The reaction rni~ture was ~v~luul~bd in-vacuo to dryness, ~ nl in 100 ml of 33% Me2NEIlEtOH and stirred overrlight at room ~
The 601ution was ev~-~uL~ ,d in-vacuo to dryness, dissolved in 50 ml of 20% K2C03 and e ~clyul~Le~ again in-v~cuo to dryness. 50 ml of water were added to the residue and the solution, acidified with 37% HCI, wa6 tv~,uu~ d in-v~cuo to dryness.
The crude residue and 10.8 rol (77.20 mmol) of TEA were dissolved in 50 rnl of CH2C12, ~0 ml of THF and 100 ml of CH3CN.
3.00 g (22.20 rnmol) of (S)-(-)-~-ethylbt ll~yl~-LuiL e, 0.78 g (5.78 mmol) of N-]I~YdLU~ dJ~:LL~ UL~ ;a,.ole (HOBT) and 11.9 g (57.90 mmol) of DCC were added and the solution was stirred at room l ~ , ., overnight.

` 2191352 W0 95132948 P~ 7~ .
The t,.~wu;LaL~d d;. ~..lùhw~ylu~;d was filtered off and the organic layer c ~ a~ aLe:d in-vacuo to dryness.
The brown oily residue was dissolved in 100 rri of CH2Cl2 and the precipitate was filtered off. The filtrate was e~tracted three times with 40% citric acid. The acqueous layer, basified with solid K2CO3, was e~tracted with CH2C12; the organic solution dried over Na2SO4 and LpU' ak:d in-vacuo to dryness afforded 10 g of a brown oil.
The crude product was flash cL~ h~d on 230-400 mesh silica gel, eluting with a mi~ture of i-Pr2O/CH2Cl2 9: I to afford 2.5 g of a white solid which was dissolved in toluene and left overnight.
The DCU ~IL . ~y;~Led was filtered and the solution, treated with ethanolic HCl, was l::va~u~ in-uacuo to drynes6. The crude product was recrystallized from a mi~ture of toluenelEtOH to yield 0.7 g of the pure title ~ r mrn lntl as colourless crystals.
C28H29N30-HCl M.P. = 164-167 C
M.W. = 460.02 [aJD20 = + 25.3 (c = 1, MeOH) I.R. (KBr): 3440; 3150; 3020; 2660; 2460;1650;1540 cm~l.
300 MHz 1H-NMR (DMSO-d6, 353 K): o 9.70 (s br, lH); 8.10 (d, lH); 7.85 (dd, lH); 7.80 (s br. lH); 7.~0-7.10 (m, 12H);
5.15 (dt, lH); 4.38-4.20 (m, 2H); 2.30 (s, 3EI); 2.22 (s, 6H); 2.10-1.82 (m, 2H); 1.00 (t, 3H).
MS OEI; source 180 C; 70 V; 200 mA): 423 (M+.), 380, 288.

(S~N~ E~lLy~ l)-3 '' y1-7 - y-2-pheIIyl4Ul~LOIi~C 9 ~< L'L ~1_ Prepared as described in E~. 1, starting from 1.27 g ( 4.09 mmol) of crude 3--methyl-7-methox,7-2-p~ yluu;~ ~G1;LLC 1 1 aLi,uuyl~.Llc,LL,le, 0.55 g (4.09 mmol) of (S)-(-)-a-ethyll,~l~yiaLLu-le and 1.71 ml (12.27 mmol) of TEA in 24 r~l of dry CH2C12 and 1 ml of DMF to help solubility. The reaction mi2~ture was stirred 12 hours at room ~.~ . .u.~.
After being rnnr~nt.~ylt~t~ in-uacuo to dryness, the residue was dissolved in CH2C12 (30 ml) and washed with 10% NaHCO3, 5% citric acid and brine.
The organic solution was dried over Na2SO4 and c ~alJulal;c~ -vacuo to dryness to obtain 1.87 g of a crude product, which was flash WLL~ hed on 230-400 mesh silica gel, eluting with a mi~ture of woss/32s4s ~ 2 1 9~ 352 P ~
he~cane/EtOAc 70: 30 to afford 0.350 g of a yellow oil.

M.W. = 410.51 I.R. (KBr): 3240; 2965; 2930;1635;1535;1220 cm~1.
EXA~LE 114 (S)-N-(a-Ethylbellzyl)~ yl-2-~ inP~
0.75 g (2.64 mmol) of 3-ar~ino-5-methyl-2-phenylquinolino ~ ~bu~yLc acid were dissolved, under nitrogen ~ , in 30 rnl of dry 'l'ti~' and 10 rol of CH3CN.
0.38 g (2.83 mmol) of (S)-(-)--ethylb~ ,ylG~i~c and 0.69 g (5.18 r~mol) of N-LyuluJ~yb.~l~7.1~ ..1e (HOBT) were added and the reaction mi~ture was cooled at -10C.
0.61 g (2.97 mmol) of DCC, dissolved in 5 ml of CH2C12, were addçd dropwise and the solution was kept at -5- 0C for 2 hours, heated Gt 50 C
for 4 hours and then left at room ~ overnight.
The u. .,~u;LaL~ lùh~ylu . ~ G was filtered off and the solution e.G~UUIGI;~.d in-ucuo to dryness. The residue was dissolved in CH2C12 and washed with H20, sat. sol. NaHC03, 5% citric acid, sat. sol. NaHC03 and brine.
The organic layer was ser~r~t~ dried over Na2SO4 and e.a~uu~cLL~ .i in-uacuo to dry7ness; the residue was dissolved in 10 rnl~f CH2C12 and left overnight. Sûme more dicyclohe2cylurea ,u~_;u;LG~d and was filtered ûff.
The solution was O.G,UUlGLt~ in-v~cuo to dryness to obtGin 0.86 g of a crude product which was flash 1...-",~ on 230-400 mesh silicG
gel, eluting with CH2Cl2/MeOH/conc. NH40H, 90: 10: 0.5 L~ ,cLi~. ly, to afford 0.41 g of the title, onnroll n~ as an ûil.

M.W. = 395.50 I.~ (KBr): 3480; 3390; 3230; 3020;1635;1615;1545 cm-1.

(S)-N-(a-E~Lyll,~yl)-3 '' y 5 "1yl-2-pl~
P
1.29 g (4.40 mmol) of 3-methoxy-5-methyl-2-pht:lly~ n~-4-calbu~ylic WO 9513294B .' ~ 3 5 2 P~
acid were dissolved, under nitrogen s~ -t~ e, in 40 ml of dry THF and 20 ml of CH3CN.
0.63 g (4.62 mmol) of (S)-(-)-o-ethylbc~ ~yl~hle and 1.13 g (8.36 mmol) of N-llydlu..yl,.~ (HOBT) were added and the reaction mi~ture wa6 cooled at -10C.
1.0 g (4.84 mmol) of DCC, dissolved in 5 ml of CH2C12, were added dropwise and the solution was kept at -5- 0C for 2 hours, heated at 50 C
for 4 hours and then left at room ~ . O overnight.
The ~ ;kL~d di~loL~ylulc~ was filtered off and the solution o.O.~v~O.LcJ in-vacuo to dryness. The residue was dissolved in CH2C12 and washed with H2O, sat. sol. NaHCO3, 5% citric acid, sat. sol. NaHCO3 and brine.
The organic layer was seF~r~r~, dried over Na2S04 and o .~Lyu~lL. d in-uacuo to dryness; the residue was dissolved in 20 ml of CH2Cl2 and left overnight. Some more dicyclohexylurea ~I c~ ;~iLhl ed and was filtered off.
The solution was ev~ ed in-vacuo to dryness to obtain 2.45 g of a crude product which was flash ~. .. ~ on 230-400 mesh silica gel, eluting with he~ane/EtOAc 7: 2 ~ - .~;..;..~ 0.5% of conc. NH40H, to afford 0.28 g of the title r~mrolln~l as an oil.

M.W. = 410.52 LR. ~KBr): 3270; 3020; 1635;1535 cm~1.

WO95/32948 2 1 9 1 352 P~
7 ,~ t ~ x u ~ u ~_ u ~
~N ~ O ~ O 0 `O O 1-- _ ~ -- X ~ ~D ~ X
0~ ~,~ " U ~ ~ =. r ~ ~
~ ot C C c ct c L` ~ -- U ~ ~ U
U
~ c ~ ~ ~ ~ e ~ ~
r 2 r ~ r ~ ~ ~, 1 o z =
o ~ ..... .:
'r T r ~r r r ~ r ~ ~ r ~ ;
. ~ r ~ ~ r r ~ X r r r r r r r r e~, ~ X = ~ r r ~: :C r: r = = r ~ ~ r t~ 8~ 8 ~ i E ~
s s ~ f ~
,.
y ~ ~ o~ r~' O O O O t' o ~O o ~

SUBSTITUTE SHEET (RULE 26) _ . . _ , . . . . . .

W095/32948 ` ~ 21 ~ 1352 r~
O ~
o~ O ~ Y ~
~c ~ ~ ~ ~c o c 'O
L ~ R~ ~ ~
~ y~
~ _.
~s ~ s ~Z ~s Y ~ ~
o~
æ = = = = =
= = = = = = Z: =
= = = ~ = ~ = =
C~
e y O

Claims (6)

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY
OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:
1. A compound N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide; or solvate or salt thereof.
2. A compound according to claim 1, being (S)-(-)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide.
3. A pharmaceutical composition comprising a compound according to claim 1 or claim 2, and a pharmaceutically acceptable carrier.
4. A compound according to claim 1 or claim 2, for use in the treatment and/or prophylaxis of pulmonary disorders, skin disorders and itch, neurogenic inflammation and CNS disorders, convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders, allergic rhinitis, neurodegenerative disorders, psoriasis and Huntington's disease.
5. The use of a pharmaceutically effective amount of N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide or solvate or salt thereof for the treatment and/or prophylaxis of pulmonary disorders, skin disorders and itch, neurogenic inflammation and CNS disorders, convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders, allergic rhinitis, neurodegenerative disorders, psoriasis and Huntington's disease.
6. The use of a pharmaceutically effective amount of N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide or solvate or salt thereof in the manufacture of a medicament for the treatment and/or prophylaxis of pulmonary disorders, skin disorders and itch, neurogenic inflammation and CNS disorders, convulsive disorders, epilepsy, renal disorders, urinary incontinence, ocular inflammation, inflammatory pain, eating disorders, allergic rhinitis, neurodegenerative disorders, psoriasis and Huntington's disease.
CA002191352A 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists Expired - Fee Related CA2191352C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002257662A CA2257662C (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
ITMI94A001099 1994-05-27
IT94MI001099A ITMI941099A1 (en) 1994-05-27 1994-05-27 KINOLINIC DERIVATIVES
ITMI95A000494 1995-03-14
IT95MI000494 IT1293558B1 (en) 1995-03-14 1995-03-14 New tachykinin receptor antagonising quinoline derivs. - used for treating pulmonary disorders, CNS disorders, skin disorders, neurogenic inflammation, epilepsy and inflammatory pain,etc.
PCT/EP1995/002000 WO1995032948A1 (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002257662A Division CA2257662C (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Publications (2)

Publication Number Publication Date
CA2191352A1 CA2191352A1 (en) 1995-12-07
CA2191352C true CA2191352C (en) 2001-01-30

Family

ID=26331143

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002191352A Expired - Fee Related CA2191352C (en) 1994-05-27 1995-05-23 Quinoline derivatives as tachykinin nk3 receptor antagonists

Country Status (35)

Country Link
US (5) US5811553A (en)
EP (2) EP0940391B1 (en)
JP (5) JP3664492B2 (en)
KR (1) KR100316571B1 (en)
CN (3) CN1092642C (en)
AP (1) AP578A (en)
AR (1) AR037069A2 (en)
AT (2) ATE246677T1 (en)
AU (1) AU699319B2 (en)
BG (2) BG64004B1 (en)
BR (1) BR9507788A (en)
CA (1) CA2191352C (en)
CZ (1) CZ291476B6 (en)
DE (2) DE69531458T2 (en)
DK (1) DK0804419T3 (en)
DZ (1) DZ1889A1 (en)
ES (2) ES2227769T3 (en)
FI (2) FI115052B (en)
HK (2) HK1003884A1 (en)
HU (1) HU226535B1 (en)
IL (1) IL113844A (en)
MA (1) MA23560A1 (en)
MX (1) MX9605903A (en)
MY (1) MY129596A (en)
NO (2) NO307783B1 (en)
NZ (1) NZ287442A (en)
OA (1) OA10592A (en)
PL (2) PL186075B1 (en)
PT (2) PT940391E (en)
RO (1) RO114445B1 (en)
SA (1) SA95160290B1 (en)
SK (2) SK282722B6 (en)
TW (2) TW533199B (en)
UA (1) UA51623C2 (en)
WO (1) WO1995032948A1 (en)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL186075B1 (en) * 1994-05-27 2003-10-31 Smithkline Beechem Spa Derivatives of quinoline as antagonists of tachykynin receptors nk3
AR004735A1 (en) * 1995-11-24 1999-03-10 Smithkline Beecham Spa CHINOLEIN 4-AMIDO SUBSTITUTED, A PROCEDURE FOR ITS PREPARATION, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM AND THE USE OF THE SAME FOR THE PREPARATION OF A MEDICINAL PRODUCT.
GB9524104D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
AU757836B2 (en) * 1995-11-24 2003-03-06 Smithkline Beecham Spa Quinoline derivatives
GB9524137D0 (en) * 1995-11-24 1996-01-24 Smithkline Beecham Spa Novel compounds
US6277862B1 (en) * 1995-11-24 2001-08-21 Smithkline Beecham S.P.A. Quinoline derivatives
US6100267A (en) * 1997-03-14 2000-08-08 Smithkline Beecham Corporation Quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
BR9809652A (en) * 1997-05-23 2001-09-11 Smithkline Beecham Spa Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists
US20010012846A1 (en) * 1997-05-23 2001-08-09 Glardina Giuseppe Arnaldo Maria Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists
AP1201A (en) * 1997-09-17 2003-09-01 Smithkline Beecham Corp Method for the synthesis of quinoline derivatives.
EP1652840A3 (en) * 1997-09-17 2006-05-17 Smithkline Beecham Corporation (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
US6780875B2 (en) * 1998-11-20 2004-08-24 Smithkline Beecham S.P.A. Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists
TR200101412T2 (en) * 1998-11-20 2001-10-22 Smithkline Beecham S.P.A. New compounds.
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
JP2002535274A (en) * 1999-01-25 2002-10-22 スミスクライン・ビーチャム・コーポレイション Anti-androgens and methods of treating diseases
US7037922B1 (en) 2000-03-10 2006-05-02 Neurogen Corporation Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands
ATE247652T1 (en) 1999-03-29 2003-09-15 Neurogen Corp 4-SUBSTITUTED QUINOLINE DERIVATIVES AS NK-3 AND/OR GABA(A) RECEPTOR LIGANDS
AU4802500A (en) 1999-04-26 2000-11-10 Neurogen Corporation 2-aminoquinolinecarboxamides: neurokinin receptor ligands
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
WO2002013825A1 (en) * 2000-08-11 2002-02-21 Smithkline Beecham P.L.C. Novel pharmaceutical use of quinnoline derivatives
GB0028964D0 (en) * 2000-11-28 2001-01-10 Smithkline Beecham Spa Novel compounds
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
EP1377567B1 (en) * 2001-04-11 2005-12-21 GlaxoSmithKline S.p.A. Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
US20040152727A1 (en) * 2001-05-18 2004-08-05 Hay Douglas William Pierre Novel use
AU2003244080A1 (en) * 2002-06-26 2004-01-19 Kyowa Hakko Kogyo Co., Ltd. Phosphodiesterase inhibitor
GB0228287D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0228288D0 (en) * 2002-12-04 2003-01-08 Smithkline Beecham Corp Chemical compounds
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
WO2005061545A2 (en) 2003-12-22 2005-07-07 Glaxo Group Limited Nogoa antibodies for the treatment of alzheimer disease
JP2007520543A (en) 2004-02-04 2007-07-26 ファイザー・プロダクツ・インク Substituted quinoline compounds
US20070244152A1 (en) * 2004-03-25 2007-10-18 Lowy Martin T Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders
US20070178151A1 (en) * 2004-03-30 2007-08-02 Vlasios Andronis Spray dried pharmaceutical compositions
BR122018075478B8 (en) 2004-06-24 2023-10-31 Vertex Pharma atp link cassette carrier modulators
US8354427B2 (en) * 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
GB0417559D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0417560D0 (en) * 2004-08-06 2004-09-08 Merck Sharp & Dohme Therapeutic compounds
GB0425077D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425075D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0425076D0 (en) * 2004-11-12 2004-12-15 Smithkline Beecham Corp Novel compounds
GB0428233D0 (en) * 2004-12-23 2005-01-26 Glaxo Group Ltd Compounds
MX2007014831A (en) * 2005-06-03 2008-02-15 Astrazeneca Ab Quinoline derivatives as nk3 anatgonists.
CN101208304A (en) * 2005-06-23 2008-06-25 阿斯利康(瑞典)有限公司 Quinoline 3-sulfonate esters as NK3 receptor modulators
GB0515580D0 (en) 2005-07-29 2005-09-07 Merck Sharp & Dohme Therapeutic compounds
US20080194623A1 (en) * 2005-08-02 2008-08-14 Labaw Clifford S Method for the Synthesis of Quinoline Derivatives
WO2007018465A1 (en) * 2005-08-11 2007-02-15 Astrazeneca Ab Amide alkyl pyridiyl quinolines as nk3 receptor modulators
JP2009504642A (en) * 2005-08-11 2009-02-05 アストラゼネカ・アクチエボラーグ Oxopyridylquinolinamide as modulator of NK-3 receptor
AR058051A1 (en) * 2005-09-21 2008-01-23 Astrazeneca Ab ALQUILNITRILO QUINOLINAS. OBTAINING PROCESS AND PHARMACEUTICAL COMPOSITIONS.
AR057130A1 (en) 2005-09-21 2007-11-14 Astrazeneca Ab ALKYL SULFOXIDE QUINOLINS AND A PHARMACEUTICAL COMPOSITION
WO2007035156A1 (en) * 2005-09-21 2007-03-29 Astrazeneca Ab N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands
TW200804288A (en) * 2005-12-12 2008-01-16 Astrazeneca Ab Alkylsulphonamide quinolines
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
JP2009521468A (en) * 2005-12-24 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Quinolin-4-one derivatives as regulators of ABC transporters
AU2006332726B2 (en) 2005-12-28 2012-12-13 Vertex Pharmaceuticals Incorporated. Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN101410392A (en) * 2006-01-27 2009-04-15 阿斯利康(瑞典)有限公司 Amide substituted quinolines
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
MX2009010059A (en) 2007-03-22 2009-10-12 Astrazeneca Ab Quinoline derivatives for the treatment of inflammatory diseases.
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
US8173639B2 (en) 2007-04-26 2012-05-08 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
US8614326B2 (en) * 2007-08-22 2013-12-24 Allergan, Inc. Therapeutic quinoline and naphthalene derivatives
WO2009049791A2 (en) * 2007-10-15 2009-04-23 F. Hoffmann-La Roche Ag Radiolabeled nk3 receptor antagonist
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
CN102123998A (en) * 2008-06-23 2011-07-13 H.隆德贝克有限公司 Isoquinolinone derivatives as nk3 antagonists
US8242134B2 (en) 2008-09-15 2012-08-14 H. Lundbeck A/S Isoquinolinone derivatives as NK3 antagonists
JP2012505842A (en) 2008-10-20 2012-03-08 ハー・ルンドベック・アクチエゼルスカベット Isoquinolinone derivatives as NK3 antagonists
NZ624460A (en) 2009-03-20 2015-12-24 Vertex Pharma Process for making modulators of cystic fibrosis transmembrane conductance regulator
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
US8487102B2 (en) * 2010-04-20 2013-07-16 Hoffmann-La Roche Inc. Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US9346814B2 (en) 2012-01-17 2016-05-24 Universiteit Antwerp FAP inhibitors
CN104470518A (en) 2012-02-27 2015-03-25 沃泰克斯药物股份有限公司 Pharmaceutical composition and administration thereof
CN102702099A (en) * 2012-06-21 2012-10-03 江苏恩华药业股份有限公司 Preparation method of (S)-3-hydroxy-2-phenyl-N-(1-phenylpropyl) quinoline-4-formamide
EP2986293A1 (en) 2013-04-19 2016-02-24 Astrazeneca AB A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos)
EP3160469B1 (en) 2014-06-25 2021-04-28 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
WO2016004035A1 (en) * 2014-07-01 2016-01-07 Icahn School Of Medicine At Mount Sinai 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases
CN107074773A (en) 2014-09-09 2017-08-18 拜耳制药股份公司 Substituted N, the formamide of 2 biaryl quinolin 4 and application thereof
MX370450B (en) 2014-10-07 2019-12-13 Vertex Pharma Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator.
JP2018512404A (en) 2015-03-18 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト Substituted N-bicyclo-2-aryl-quinoline-4-carboxamide and uses thereof
ES2753539T3 (en) * 2015-05-18 2020-04-13 Nerre Therapeutics Ltd NK-1 / NK-3 receptor antagonist for the treatment of hot flashes
WO2017072629A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical combination of nk3 receptor antagonist and biguanides
WO2017153235A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-3-aryl-1-naphthamides and use thereof
WO2017153231A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof
WO2017153234A1 (en) 2016-03-09 2017-09-14 Bayer Pharma Aktiengesellschaft Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof
CN105884626B (en) * 2016-05-04 2017-10-20 龙曦宁（上海）医药科技有限公司 A kind of synthetic method of 2 aminoidan derivatives and products thereof
WO2018189011A1 (en) * 2017-04-10 2018-10-18 Bayer Aktiengesellschaft Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof
TWI770157B (en) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
US11458129B2 (en) 2017-11-02 2022-10-04 California Institute Of Technology Neurokinin antagonists and uses thereof
US20210401821A1 (en) * 2018-11-15 2021-12-30 Kyushu University, National University Corporation Prophylactic or therapeutic agent and medicinal composition for il-31-mediated disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1560489A (en) * 1976-05-21 1980-02-06 Fisons Ltd Pharmaceutical compositions
FR2538388B1 (en) * 1982-12-24 1985-06-21 Pharmuka Lab NOVEL NAPHTHALENE- OR AZANAPHTHALENECARBOXAMIDE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
DE3905339A1 (en) * 1989-02-22 1990-09-06 Basf Ag CHINOLINE-4-CARBONATEURED DERIVATIVES AND THEIR USE
US5037835A (en) * 1989-10-24 1991-08-06 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
US4992448A (en) * 1989-10-24 1991-02-12 Hoechst-Roussel Pharmaceuticals Inc. Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders
EP0449565B1 (en) * 1990-03-26 1997-05-14 Matsushita Electric Industrial Co., Ltd. Photosensitive material for electrophotography
DE69315920T2 (en) * 1992-09-04 1998-06-10 Takeda Chemical Industries Ltd Condensed heterocyclic compounds, their production and use
US5434158A (en) * 1994-04-26 1995-07-18 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin-3 antagonists
PL186075B1 (en) * 1994-05-27 2003-10-31 Smithkline Beechem Spa Derivatives of quinoline as antagonists of tachykynin receptors nk3
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists

Also Published As

Publication number Publication date
BR9507788A (en) 1997-09-23
IL113844A (en) 2005-05-17
AU699319B2 (en) 1998-12-03
BG64004B1 (en) 2003-09-30
US7482458B2 (en) 2009-01-27
US20060160846A1 (en) 2006-07-20
DE69533408D1 (en) 2004-09-23
US20030236281A1 (en) 2003-12-25
SK151496A3 (en) 1997-07-09
EP0940391B1 (en) 2004-08-18
FI964712A (en) 1997-01-23
JP2000026314A (en) 2000-01-25
EP0940391A3 (en) 1999-11-10
UA51623C2 (en) 2002-12-16
AU2616495A (en) 1995-12-21
DE69533408T2 (en) 2005-09-08
HK1003884A1 (en) 1998-11-13
DK0804419T3 (en) 2003-11-24
NO326714B1 (en) 2009-02-02
AP9500745A0 (en) 1995-07-31
ES2227769T3 (en) 2005-04-01
DZ1889A1 (en) 2002-02-17
TW533199B (en) 2003-05-21
EP0940391A2 (en) 1999-09-08
AR037069A2 (en) 2004-10-20
KR100316571B1 (en) 2002-05-30
NO965036D0 (en) 1996-11-26
CZ291476B6 (en) 2003-03-12
EP0804419B1 (en) 2003-08-06
CN1428145A (en) 2003-07-09
SA95160290B1 (en) 2006-06-21
FI990268A (en) 1999-02-10
SK282721B6 (en) 2002-11-06
TW427977B (en) 2001-04-01
CA2191352A1 (en) 1995-12-07
JP2005068155A (en) 2005-03-17
WO1995032948A1 (en) 1995-12-07
CN1156451A (en) 1997-08-06
NO991813L (en) 1997-01-24
US20050096316A1 (en) 2005-05-05
FI115052B (en) 2005-02-28
HU226535B1 (en) 2009-03-30
JP2002179594A (en) 2002-06-26
FI119721B (en) 2009-02-27
CN1092642C (en) 2002-10-16
PL317381A1 (en) 1997-04-01
SK4799A3 (en) 1999-06-11
AP578A (en) 1997-03-26
ATE273959T1 (en) 2004-09-15
CN1276211A (en) 2000-12-13
NO965036L (en) 1997-01-24
HK1024469A1 (en) 2000-10-13
MX9605903A (en) 1998-08-30
NO307783B1 (en) 2000-05-29
IL113844A0 (en) 1995-08-31
NO991813D0 (en) 1999-04-16
PL186075B1 (en) 2003-10-31
PT940391E (en) 2004-12-31
PT804419E (en) 2003-12-31
ES2204952T3 (en) 2004-05-01
RO114445B1 (en) 1999-04-30
ATE246677T1 (en) 2003-08-15
JPH10500697A (en) 1998-01-20
SA95160290A (en) 2005-12-03
FI990268A0 (en) 1999-02-10
OA10592A (en) 2002-08-27
JP2007126475A (en) 2007-05-24
NZ287442A (en) 1998-05-27
SK282722B6 (en) 2002-11-06
US6608083B1 (en) 2003-08-19
US5811553A (en) 1998-09-22
BG103181A (en) 1999-09-30
MY129596A (en) 2007-04-30
BG101008A (en) 1997-08-29
DE69531458T2 (en) 2004-08-05
CZ347096A3 (en) 1997-10-15
JP3664492B2 (en) 2005-06-29
HUT76286A (en) 1997-07-28
DE69531458D1 (en) 2003-09-11
PL186665B1 (en) 2004-02-27
FI964712A0 (en) 1996-11-26
HU9603262D0 (en) 1997-01-28
EP0804419A1 (en) 1997-11-05
MA23560A1 (en) 1995-12-31

Similar Documents

Publication Publication Date Title
CA2191352C (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
US6743804B2 (en) Quinoline derivatives as NK3 antagonists
ITMI981902A1 (en) CYCLIC AMINE DERIVATIVES THAT ARE ANTAGONISTS OF CCR-3 RECEPTORS PHARMACEUTICAL COMPOSITIONS CONTAINING THEM METHODS FOR THEIR
AU722451B2 (en) Salts of quinoline derivatives as NK3 antagonists
RU2155754C2 (en) Quinoline derivatives as techychinin nk3 receptor antagonists
CA2257662C (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
AU757836B2 (en) Quinoline derivatives
ITMI950495A1 (en) Quinoline derivatives.
AU5784501A (en) Quinoline derivatives as tachykinin NK3 receptor antagonists
ITMI950494A1 (en) KINOLINIC DERIVATIVES
PL188872B1 (en) Quinoline derivatives as tachykinin nk3 receptor antagonists
AU1216299A (en) Quinoline derivatives as tachykinin NK3 receptor antagonists

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed